

Development of a Copper-catalyzed Amidation-Base-promoted Cyclization

Sequence for the Synthesis of 2-Aryl- and 2-Vinyl-4-quinolones

By

Carrie Preston Jones

B.A. Chemistry  
Williams College, 2002

SUBMITTED TO THE DEPARTMENT OF CHEMISTRY IN PARTIAL FULFILLMENT OF  
THE REQUIREMENT FOR THE DEGREE OF


MASTER OF SCIENCE IN ORGANIC CHEMISTRY


AT THE


MASSACHUSETTS INSTITUTE OF TECHNOLOGY


SEPTEMBER 2007

© Massachusetts Institute of Technology, 2007  
All rights reserved

Signature of Author:..........  
Department of Chemistry  
June 26, 2007

Certified by:..........  
Stephen L. Buchwald  
Camille Dreyfus Professor of Chemistry  
Academic Advisor

Accepted by:..........  
Robert W. Field  
Chairman, Department Committee on Graduate Students



ARCHIVES



Development of a Copper-catalyzed Amidation-Base-promoted Cyclization  
Sequence for the Synthesis of 2-Aryl- and 2-Vinyl-4-quinolones

By

Carrie Preston Jones

Submitted to the Department of Chemistry  
on June 26, 2007 in Partial Fulfillment of the  
Requirements for the Degree of Master of Science in  
Chemistry

ABSTRACT

A direct two-step method for the preparation of 2-aryl- and 2-vinyl-4-quinolones that utilizes a copper-catalyzed amidation of *ortho*-halophenones followed by a base-promoted Camps cyclization of the resulting *N*-(2-keto-aryl)amides is described. With CuI, a diamine ligand, and base as the catalyst system, the amidation reactions proceed in good yields for a range of aryl, heteroaryl, and vinyl amides. The subsequent Camps cyclization efficiently provides the desired 4-quinolones using the conditions that are described.

Thesis Supervisor : Stephen L. Buchwald  
Title: Camille Dreyfus Professor of Chemistry

## **Acknowledgments**

I would like to thank Stephen Buchwald for giving me the great opportunity to do research in his group and for being so supportive. I would also like to thank the members of the Buchwald group for all your help. I feel very honored to have met such genuine labmates and I greatly value the friendships I have made through MIT. I would like to thank my chemistry mentors both in college (Lee) and at Merck (Ping, Tom, Linus, and James) for their advice and inspiration even now- I am very grateful for the opportunity I had to work with you. I would like to thank my family for supporting me through all my endeavors, especially my brother, Kevin, for emotional support and biweekly lunches, and my friends Karen and Laddie for continual uplifting and because they too love complaining. Lastly, I want to thank Brian for enduring grad school and for wanting me to be happy no matter what- your thoughtfulness, humor, and understanding have been invaluable to me.

## Preface

Parts of this thesis have been adapted from the following article co-written by the author.

“Sequential Cu-Catalyzed Amidation-Base-mediated Camps Cyclization: A Two-step Synthesis of 2-Aryl-4-quinolones from *ortho*-Halophenones” Jones, C. P.; Anderson, K. W.; Buchwald, S. L. *J. Org. Chem.* **2007**, *submitted*.


## Table of Contents

### Development of a Copper-catalyzed Amidation-Base-promoted Cyclization Sequence for the Synthesis of 2-Aryl- and 2-Vinyl-4-quinolones


I.	Introduction	7
II.	Results and Discussion	15
III.	Experimental Section	23
IV.	References	45
V.	Appendix A: Selected NMR Spectra	49
VI.	Appendix B: Curriculum Vitae	67

## I. Introduction


The metal-catalyzed formation of aromatic C-N bonds has become increasingly important in organic synthesis over the past decade.<sup>1</sup> Palladium and copper catalyst systems for cross-coupling aryl halides and nitrogen nucleophiles have recently found application in the synthesis of nitrogen-containing heterocycles. Several efficient methods have been developed in which a sequential metal-catalyzed C-N bond-forming/cyclization process yields a heterocycle. For example, Ma has reported a one-pot procedure for synthesizing benzimidazoles in which a Cu-catalyzed amination of iodoacetanilides provides an *ortho*-aminoanilide that can undergo a thermal or acid-promoted cyclization to the benzimidazole (Scheme 1, eq. 1).<sup>2</sup> Similarly, Cu-catalyzed aminations of haloenynes with hydrazines and amines followed by hydroamidation yield pyrazoles or pyrroles, respectively (Scheme 1, eq. 2).<sup>3</sup> 2-Naphthyridinones and 2-quinolones can be prepared using a Pd-catalyzed amidation/intramolecular aldol condensation domino synthesis (Scheme 1, eq. 3).<sup>4</sup> Indoles<sup>5</sup> and pyrroles<sup>6</sup> have also been synthesized *via* similar sequences.



#### Synthesis of Benzimidazoles



#### Synthesis of Substituted Pyrroles and Pyrazoles




#### Synthesis of 2-Quinolones and 2-Naphthyridinones

**Scheme 1.** Metal-Catalyzed C-N Bond-formation/Cyclization Methods for the Synthesis of Heterocycles.

Nitrogen-containing heterocycles are present in a variety of biologically-active compounds that can be used in a wide range of therapeutic areas.<sup>7</sup> Specifically, 4-quinolone derivatives<sup>8</sup> exhibit antibacterial activity, and several quinolones, such as oxolinic acid and ciprofloxacin, have emerged as potent antibiotics (Figure 1).<sup>7</sup> More recently certain 2-aryl-4-quinolones and compounds containing these structures have been studied as potential treatments for a range of




diseases<sup>9</sup> as they exhibit antimitotic,<sup>10</sup> antiplatelet,<sup>9b</sup> and antiviral<sup>9f,g,i</sup> activities and have positive cardiac effects.<sup>9a</sup>





**Figure 1.** Structures of 4-Quinolones with Antibiotic Activity.

Multiple methods have been reported for the synthesis of 2-aryl-4-quinolones<sup>8a</sup> including two classical approaches, the Conrad-Limpach and Niementowski reactions.<sup>11</sup> The Conrad-Limpach synthesis involves the condensation of a  $\beta$ -ketoester with an aniline followed by a high temperature thermal cyclization (Scheme 2, eq. 1).<sup>11a</sup> Modifications of the method have incorporated the use of  $\beta$ -ketoamides and have succeeded in lowering the temperature of the cyclization by employing polyphosphoric acid (PPA) (Scheme 2, eq. 2).<sup>9f,12</sup> Recently several groups have reported milder conditions in which Eaton's reagent ( $P_2O_5/MeSO_3H$ ) is used for the cyclization to 2- or 3-carboxy-4-quinolones at temperatures below 90 °C (Scheme 2, eq. 3).<sup>13</sup> This new protocol has not been demonstrated for the synthesis of 2-aryl-4-quinolones.

### Conrad-Limpach Reaction




### Modified Conrad-Limpach Reactions





**Scheme 2.** Conrad-Limpach Reaction and Modifications.

The Niementowski reaction employs the condensation of anthranilic acid with a ketone or an aldehyde for the synthesis of 4-quinolones (Scheme 3, eq. 1).<sup>11b</sup> Initially when acetophenone was used in the reaction with anthranilic acid, only a 3-5% yield of the 2-phenyl-4-quinolone was obtained. The yield was improved to 84% by using the diethyl acetal of acetophenone as the starting material at high temperature (Scheme 3, eq. 2).<sup>14</sup> Even with this improvement, the temperatures employed in the reaction were still very high. Addressing these harsh reaction conditions, a new modification of the Niementowski synthesis was recently developed in which anthranilic acid was converted *in situ* to an iminoketene that cyclized *via* a  $[4\pi + 2\pi]$  cycloaddition with a ketone to yield the desired 4-quinolones (Scheme 3, eq. 3).<sup>15</sup> However, this synthetic route requires anthranilic acid derivatives that can withstand reaction with thionyl chloride. Less traditional syntheses of these compounds<sup>16</sup> make use of transition metals,

### Niementowski Reaction




### Modified Niementowski Reactions




### Scheme 3. Niementowski Reaction and Modifications.

including palladium-catalyzed carbonylation,<sup>17</sup> titanium-mediated reductive coupling,<sup>18</sup> and ruthenium-catalyzed reduction reactions (Scheme 4).<sup>19</sup>


### Palladium-catalyzed Carbonylative Coupling/Cyclization



### Titanium-mediated Reductive Coupling




### Ruthenium-catalyzed Reduction/Cyclization




**Scheme 4.** Metal-promoted Syntheses of 4-Quinolones.

The base-promoted cyclization of *N*-(keto-aryl)amides (the Camps cyclization)<sup>20</sup> has seen widespread utilization for the synthesis of quinolones (Scheme 5).<sup>9c,f,i,10b-f,21</sup> Camps'



**Scheme 5.** Camps Quinolone Synthesis.


intramolecular aldol condensation was used in the scalable synthesis of BILN 2061, a drug candidate for the treatment of Hepatitis C Virus (Scheme 6, eq. 1),<sup>9i</sup> as well as in the preparation of the indole-substituted 4-quinolone target for SAR studies aimed at developing potent 5 $\alpha$ -reductase inhibitors (Scheme 6, eq. 2).<sup>9c</sup> Several different bases and solvents have been employed in the Camps method for cyclizing *N*-(keto-aryl)amides and recently a microwave protocol was reported for the transformation.<sup>21d</sup>




**Scheme 6.** Pharmaceutical Applications of the Camps Quinolone Synthesis.

Crucial to the utility of the Camps cyclization is the ability to access the *N*-(keto-aryl)amide starting materials. Known methods for the syntheses of these Camps precursors comprise condensations of *o*-aminoacetophenones and carboxylic acids<sup>9c</sup> or acid chlorides (Scheme 7, eq. 1),<sup>9h,10b-e,21b,22</sup> synthesis and subsequent opening of a benzoxazinone with the dianion of an *N*-



substituted acetamide (Scheme 7, eq. 2),<sup>20b,21a</sup> or Friedel-Crafts acylations of anilides, which often result in mixtures of products (Scheme 7, eq. 3 and 4).<sup>9i,10f,21c</sup>



Amide Formation from Anilines and Acid Chlorides



*N*-(Keto-aryl)amides through a Benzoxazinone Intermediate




Friedel-Crafts Acylations for Installing *o*-Acetyl Groups

**Scheme 7.** Methods for the Formation of *N*-(Keto-aryl)amides.

In the next section we describe a simple sequence which employs a copper-catalyzed amidation reaction of 2-halophenones with aryl, heteroaryl, and vinyl amides as a means to access *N*-(keto-aryl)amides and their subsequent Camps cyclizations to 2-aryl- or 2-vinyl-4-quinolones. We also demonstrate the ability of these same amidation products to undergo McMurry titanium-mediated coupling reactions to form indoles as developed by Fürstner.<sup>18,22,23</sup>

## II. Results and Discussion


Considering the established Camps cyclization for the synthesis of 2-aryl-4-quinolones, we envisioned that a cross-coupling reaction could be applied to prepare the *N*-(keto-aryl)amide Camps precursor. Retrosynthetic analysis of the *N*-(keto-aryl)amides suggested that a metal-catalyzed C-N bond-forming amidation approach could be utilized to install the amide portion of the compounds using *ortho*-halophenones as starting materials (Scheme 8). This approach to the *N*-(keto-aryl)amide intermediates would allow easy access to different R<sup>3</sup> groups by simply using diverse aryl (or vinyl) amides.



**Scheme 8.** Retrosynthetic Analysis of 2-Substituted-4-quinolones.

Based on the Cu(I)-catalyzed amidation of aryl halides in the presence of 1,2-diamine ligands developed in our group,<sup>24</sup> we focused on the application of this methodology to aryl halides with *ortho*-substituted ketones. As a test case, 2-bromoacetophenone was allowed to react with

benzamide using 10 mol% CuI, 20 mol% ligand, and 2 equivalents of K<sub>2</sub>CO<sub>3</sub> in toluene at 110 °C for 24 hours. In a preliminary screen employing ligands L1-L3, the reaction with L1 proceeded in the highest yield (Table 1, entry 1). We observed that 2-hydroxyacetophenone was generated from the reaction of 2-bromoacetophenone with traces of water, presumably introduced into the reaction mixture by moisture in the base. The formation of this by-product could be suppressed and the yield of the desired product improved by the use of activated molecular sieves or by a reduction in the reaction temperature to 90 °C (Table 1, entry 4).



**Figure 2.** Diamine Ligands for Cu-catalyzed Amidation Reactions of Aryl Halides.

**Table 1.** Ligand Screening for Cu-Catalyzed Amidation with Benzamide.

entry	ligand	CuI (mol%)	temp (°C)	mol. sieves (5Å)	GC conversion <sup>a</sup> (%)	GC yield <sup>a</sup> (%)
1	<b>L1</b>	10	110	no	98	78
2	<b>L2</b>	10	110	no	100	54
3	<b>L3</b>	10	110	no	100	75
4	<b>L1</b>	10	90	yes	100	94
5	<b>L1</b>	0	90	yes	3	0
6	none	0	90	yes	2	0
7	none	10	90	yes	76	66

<sup>a</sup>GC yields and conversions are the average of two or more runs.

In a series of control experiments, we found that the reaction did not proceed in the absence of CuI indicating that the amidation reaction does not follow a simple nucleophilic aromatic



substitution mechanism (Table 1, entries 5 and 6).<sup>25</sup> The reaction did however yield product in the absence of ligand (Table 1, entry 7). As reported previously in the Cu-catalyzed synthesis of biaryl ethers, certain electron-withdrawing groups in the *ortho* position of the aryl halide have the ability to coordinate to copper and hasten the Ullmann-type reaction.<sup>26</sup> Presumably, in this amidation reaction the *o*-accelerating acetyl group had the ability to promote the coupling without the diamine ligand present. Nevertheless, the diamine ligand did enhance the rate of the amidation reaction as the ligand-free reaction did not reach completion after 24 hours.


With these reaction conditions in hand, the versatility of the Cu-catalyzed amidation reaction of 2-bromophenones and 2-iodophenones was explored (Table 2). The substrate scope of the coupling reaction encompassed 2-halophenones bearing both electron-withdrawing (8-10) and electron-donating groups (11 and 12). As demonstrated by the use of 2-halopropiophenones, the amidation reaction also tolerated larger ketone substituents than the methyl group (11 and 12). The couplings proceeded with heterocyclic amides, including 2-, 3-, and 4-pyridyl amides as well as 2- and 3-thiophenecarboxamides (3-7, 10, and 12). Both aryl and alkyl vinyl amides could be cross-coupled (13 and 14), and though the cyclic secondary amide pyrrolidinone reacted in good yield (15), acyclic secondary amides were not effective coupling partners.

Though most reactions were conducted using the 2-bromophenones, the low reactivity of picolinamide (5), 2-chlorobenzamide (9), and crotonamide (14) as nucleophiles prompted us to employ the more active 2-iodophenones as substrates for these couplings.<sup>27,28</sup> However, even with the use of the 2-iodophenone, the yields for the syntheses of 9 and 14 were still only moderate. The synthesis of 9 from the 2-iodophenone could be accomplished in a one-pot procedure from the corresponding aryl bromide using a Cu-catalyzed halide exchange reaction<sup>29</sup> followed by the Cu-catalyzed amidation reaction (Scheme 9).

**Table 2.** Cu-catalyzed Amidation of 2-Halophenones.

X	product	yield (%) <sup>a</sup>	X	product	yield (%) <sup>a</sup>
Br		(1) 86 <sup>b</sup>	Br		(8) 78
Br		(2) 83	I		(9) 67 <sup>e,f</sup>
Br		(3) 80 <sup>c</sup>	Br		(10) 77
Br		(4) 86	Br		(11) 72
I		(5) 71 <sup>d</sup>	Br		(12) 72
Br		(6) 81 <sup>c</sup>	Br		(13) 77 <sup>g</sup>
Br		(7) 82	I		(14) 68 <sup>f</sup>
			Br		(15) 89 <sup>h</sup>

<sup>a</sup>Isolated yields are the average of two or more runs. <sup>b</sup>Heated to 90 °C. <sup>c</sup>Without molecular sieves. <sup>d</sup>Heated for 42 h with K<sub>3</sub>PO<sub>4</sub>. <sup>e</sup>Aryl iodide generated *in situ* from aryl bromide. <sup>f</sup>With 2 equiv K<sub>3</sub>PO<sub>4</sub>. <sup>g</sup>With 20 mol% L2. <sup>h</sup>With 5 mol% CuI, 10 mol% L1.



**Scheme 9.** Synthesis of **9** via *in situ* Formation of 2-Iodo-4-fluoroacetophenone Followed by Cu-catalyzed Amidation Reaction.

Having developed a successful method for the synthesis of *N*-(2-keto-aryl)amides, we focused on the base-catalyzed Camps cyclization to yield 2-substituted-4-quinolones. The optimal reaction conditions for the cyclization of *N*-(2-keto-aryl)amide **6** to 4-quinolone **21** were found to involve the use of 3-3.5 equivalents of NaOH in dioxane at 110 °C. The conditions proved to be generally applicable to a wide range of *N*-(2-keto-aryl)amides providing the appropriate 2-substituted-4-quinolones in good to excellent yields (Table 3). The cyclization method was also effective for the syntheses of more highly substituted quinolones **26** and **27**. Notably, when submitted to the reaction conditions, the pyrrolidinone-coupled substrate **15** provided a more complex tricyclic pyrrolo-quinolone ring system (**29**).


The workup of the 4-quinolone compounds was particularly facile as, with the exception of **29**, all the compounds shown in Table 3 could be isolated in pure form without the need to employ column chromatography; after initial concentration of the organic reaction mixture, the resulting residue was dissolved in water, and the desired products precipitated upon neutralization.

**Table 3.** Base-catalyzed Camps Cyclization to 2-Substituted-4-quinolones.

starting material	product	yield (%) <sup>a</sup>	starting material	product	yield (%) <sup>a</sup>
(1)	(16)	94	(8)	(23)	90
(2)	(17)	97	(9)	(24)	72
(3)	(18)	90	(10)	(25)	92
(4)	(19)	89	(11)	(26)	88
(5)	(20)	88	(12)	(27)	86
(6)	(21)	97	(13)	(28)	82 <sup>b</sup>
(7)	(22)	92	(15)	(29)	94

<sup>a</sup>Isolated yields are the average of two or more runs. <sup>b</sup>Heated to 90 °C.


Compound **14** has the ability to cyclize to either 2-vinyl-4-quinolone (**30**) or 4-methyl-3-vinyl-2-quinolone (**31**) depending on the nature of the base utilized (Scheme 10). With NaOH, deprotonation occurred at the  $\alpha$  position of the ketone followed by the intramolecular aldol condensation. However, the use of a weaker base ( $\text{Cs}_2\text{CO}_3$ ) afforded **31** as the major product *via*  $\gamma$ -deprotonation of the amide. In both cases, traces of the other isomer were produced, which could be readily separated by column chromatography on silica gel. Similarly, as Camps observed,<sup>20a</sup> substrates with accessible protons at the  $\alpha$  position of the amide yield a mixture of 4- and 2-quinolones rendering this method unsuitable for use with alkyl amides for the selective preparation of 2-alkyl-4-quinolones.<sup>30</sup> Unfortunately, the base-dependent selectivity observed for the synthesis of **30** and **31** was not seen for alkyl amides.



**Scheme 10.** Base-promoted Cyclizations to Synthesize **30** and **31**

Finally, the Cu-catalyzed amidation products in Table 2 were submitted to Fürstner's "instant"  $\text{TiCl}_3/\text{Zn}$  powder conditions<sup>18</sup> for the McMurry Ti-promoted coupling reaction to prepare 2- and 3-substituted indoles (Table 4). The yield was low when the obtained indole contained alkyl substituents in both the 2- and 3-positions (**37**).

**Table 4.** Ti-mediated Coupling for the Preparation of Substituted Indoles.



<sup>a</sup>Isolated yields are the average of two or more runs.

In conclusion, we have demonstrated a new two-step synthesis of 2-aryl- and 2-vinyl-4-quinolones. The Cu-catalyzed amidation reaction of 2-halophenones offers access to *N*-(2-keto-aryl)amides that readily undergo base-promoted Camps cyclization to provide the desired 4-quinolones. We have also shown the accessibility of 2- and 3-substituted indoles from the *N*-(2-keto-aryl)amides via Ti-mediated reductive coupling. These sequential methods have potential for application in the synthesis of substituted nitrogen-containing heterocycles.

### III. Experimental Section

**General Considerations.** All reactions were carried out in oven-dried resealable test tubes or Schlenk tubes under an atmosphere of argon. Potassium carbonate (Mallinckrodt or Aldrich), potassium phosphate (Riedel-de-Haën), and cesium carbonate (Chemetall) bases were stored in bulk in a glove box. Quantities of approximately 5 grams were removed from the glove box and stored in a bench-top desiccator. Sodium hydroxide pellets were crushed using a mortar and pestle and stored in the bench-top desiccator. CuI was obtained from Strem Chemicals (99.9% purity). TiCl<sub>3</sub> (99.999% purity) and Zn nanosize activated powder were both purchased from Aldrich and stored and weighed in the glove box. All three diamine ligands (**L1**, **L2**, **L3**) were obtained from Aldrich and stored in a bench-top desiccator. Amides and aryl halides were obtained from commercial sources (Aldrich, TCI, Avocado, Acros, Alfa Aesar) and used without further purification, except for 2-bromo-5-methoxypropiophenone, which was synthesized from commercially available starting materials as described in the Supporting Information. Toluene was obtained from J. T. Baker in CYCLE-TAINER kegs which were purged with argon for two hours and subsequently passed through two columns of neutral alumina and copper(II) oxide under a pressure of argon for further purification. Anhydrous 1,4-dioxane and DME were purchased from Aldrich in SureSeal<sup>®</sup> bottles. Molecular sieves (5Å) were obtained as a powder from Acros and were activated in bulk *via* flame-drying under vacuum. Silica column chromatography was performed using a Biotage SP4 Flash Purification System on KP-Sil silica cartridges.

Compounds were characterized using <sup>1</sup>H-NMR, <sup>13</sup>C-NMR, melting point, IR (KBr plate) and, in certain cases, elemental analysis. (Copies of <sup>1</sup>H-NMR and <sup>13</sup>C-NMR spectra are provided in the Supporting Information for all new compounds and any compounds that did not have

adequate elemental analysis results.) Data of known compounds were compared with existing literature characterization data and the references are given. All isolated and GC yields reported in the Results and Discussion are the average of two or more experiments. Elemental Analyses were conducted by Atlantic Microlabs, Inc., Norcross, GA. NMR spectra were obtained using Varian 500 MHz, Bruker Advance 400 MHz, or Varian 300 MHz instruments. The chemical shifts are reported in parts per million (ppm) based on the reference of the deuterated solvent. Melting points (uncorrected) were measured using a Mel-Temp II capillary apparatus. GC analysis was performed on an Agilent 6890 instrument with an FID detector and an Agilent 10m x 0.1mm DB-1 capillary column. GC yields and conversions were reported as referenced to dodecane as an internal standard. GC-MS analyses were performed on an Agilent 6850 instrument with an Agilent 5975 inert Mass Selective Detector. IR spectra were measured using a Perkin-Elmer System 2000 FT-IR. Compounds were applied in a thin film on a KBr pellet.

**General Procedure A: Amidation of *o*-halophenones.** An oven-dried resealable test tube with a Teflon stir bar was charged with amide (1.2 equiv, 0.60 mmol), CuI (10 mol%, 0.05 mmol), base (2 equiv, 1 mmol), and approximately 200 mg activated 5 Å molecular sieves. The test tube was sealed with a rubber septum and evacuated and refilled with Argon through a syringe needle (this sequence was performed three times). Under argon, *o*-halophenone (1.0 equiv, 0.50 mmol), *N, N'*-dimethylethylenediamine (L1) (20 mol%, 0.1 mmol), and toluene (1 mL) were each added *via* syringe. The rubber septum was then removed and quickly replaced with a Teflon screw-cap. The test tube was then placed in a preheated oil bath at 110 °C. The reaction was heated with stirring for 24 h and then cooled to room temperature. The reaction mixture was partitioned between EtOAc and water and the organic layer separated. The aqueous



layer was extracted with EtOAc and the organic layer combined, dried over magnesium sulfate, filtered, and concentrated *in vacuo* to remove solvent. The product was purified by column chromatography on silica gel with EtOAc and hexane.

***N*-(2-Acetyl-phenyl)-benzamide (1).**<sup>31,22</sup> Following General Procedure A, benzamide (76 mg, 0.63 mmol) was coupled with 2-bromoacetophenone (67  $\mu$ L, 0.50 mmol) using CuI (9.5 mg, 0.050 mmol), L1 (10.5  $\mu$ L, 0.985 mmol), K<sub>2</sub>CO<sub>3</sub> (140 mg, 1.0 mmol), and 200 mg activated 5 Å molecular sieves in anhydrous toluene (1 mL). The reaction was heated to 90 °C for 24 h. **1** was purified by column chromatography using a hexane-EtOAc 98:2 to 90:10 gradient. 106 mg (88% yield) of a cream-colored solid were obtained. Mp: 99-100 °C (lit mp: 100 °C (ether)).<sup>32</sup> <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  12.73 (s, 1H), 9.00 (dd, *J* = 8.5, 1.1 Hz, 1H), 8.08 (m, 2H), 7.98 (dd, *J* = 8.0, 1.5 Hz, 1H), 7.64 (m, 1H), 7.55 (m, 3H), 7.18 (ddd, *J* = 8.5, 7.3, 1.2 Hz, 1H), 2.75 (s, 3H). <sup>13</sup>C-NMR (400 MHz, CDCl<sub>3</sub>): 203.3, 166.1, 141.4, 135.4, 134.8, 132.1, 131.9, 128.9, 127.5, 122.5, 121.9, 120.7, 28.6. IR (neat, cm<sup>-1</sup>): 3222, 3064, 1679, 1650, 1607, 1585, 1450, 1359, 1313, 1247, 1166, 1099, 1073, 1028, 960, 896, 799, 756, 701, 609. Anal. calcd. for C<sub>15</sub>H<sub>13</sub>NO<sub>2</sub>: C, 75.30; H, 5.48. Found: C, 75.10; H, 5.50.

***N*-(2-Acetyl-phenyl)-3-chlorobenzamide (2).** Following General Procedure A, 3-chlorobenzamide (93 mg, 0.60 mmol) was coupled with 2-bromoacetophenone (67  $\mu$ L, 0.50 mmol) using CuI (9.5 mg, 0.050 mmol), L1 (10.5  $\mu$ L, 0.985 mmol), K<sub>2</sub>CO<sub>3</sub> (140 mg, 1.0 mmol), and 200 mg activated 5 Å molecular sieves in anhydrous toluene (1 mL). **2** was purified by column chromatography using a hexane-EtOAc 98:2 to 90:10 gradient. 112 mg (82% yield) of a white solid were obtained. Mp: 137-139 °C. <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  12.75 (s, 1H), 8.95 (d, *J* = 8.5 Hz, 1H), 8.07 (s, 1H), 7.98 (dd, *J* = 8.0, 1.4 Hz, 1H), 7.94 (ddd, *J* = 7.7, 1.7, 1.1 Hz, 1H), 7.65 (m, 1H), 7.55 (ddd, *J* = 8.0, 2.0, 1.1 Hz, 1H), 7.48 (t, *J* = 7.8 Hz, 1H), 7.20 (m, 1H),

2.74 (s, 3H). <sup>13</sup>C-NMR (400 MHz, CDCl<sub>3</sub>): 203.5, 164.7, 141.2, 136.7, 135.5, 135.1, 132.1, 132.0, 130.2, 128.2, 125.3, 122.9, 122.0, 120.8, 28.7. IR (neat, cm<sup>-1</sup>): 3185, 3068, 2920, 1684, 1644, 1608, 1584, 1523, 1452, 1359, 1315, 1258, 1170, 1076, 965, 904, 851, 798, 755, 739, 721, 611. Anal. calcd. for C<sub>15</sub>H<sub>12</sub>ClNO<sub>2</sub>: C, 65.82; H, 4.42. Found: C, 65.69; H, 4.22.

***N*-(2-Acetyl-phenyl)-isonicotinamide (3)**.<sup>9h</sup> Following General Procedure A, isonicotinamide (73 mg, 0.60 mmol) was coupled with 2-bromoacetophenone (67 μL, 0.50 mmol) using CuI (9.5 mg, 0.050 mmol), L1 (10.5 μL, 0.985 mmol), and K<sub>2</sub>CO<sub>3</sub> (140 mg, 1.0 mmol), in anhydrous toluene (1 mL). No molecular sieves were added for the synthesis of the title compound. **3** was purified by column chromatography using a hexane-EtOAc 95:5 to 50:50 gradient. 94 mg (78% yield) of a cream-colored solid were obtained. Mp: 119-120 °C (lit mp: 116-117 °C).<sup>33</sup> <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): δ 12.91 (s, 1H), 8.96 (dd, *J* = 8.5, 0.9 Hz, 1H), 8.85 (d, *J* = 5.3 Hz, 2H), 8.01 (dd, *J* = 8.0, 1.5 Hz, 1H), 7.91 (dd, *J* = 4.6, 1.6 Hz, 2H), 7.67 (m, 1H), 7.24 (ddd, *J* = 8.5, 7.3, 1.2 Hz, 1H), 2.75 (s, 3H). <sup>13</sup>C-NMR (300 MHz, CDCl<sub>3</sub>): 203.6, 163.9, 150.9, 141.8, 140.7, 135.6, 132.0, 123.3, 122.0, 121.1, 120.8, 28.7. IR (neat, cm<sup>-1</sup>): 3205, 3120, 3029, 1678, 1645, 1611, 1586, 1535, 1449, 1410, 1362, 1317, 1251, 1161, 1062, 963, 836, 756, 692, 677. Anal. calcd. for C<sub>14</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub>: C, 69.99; H, 5.03. Found: C, 69.96; H, 5.09.

***N*-(2-Acetyl-phenyl)-nicotinamide (4)**. Following General Procedure A, nicotinamide (73 mg, 0.60 mmol) was coupled with 2-bromoacetophenone (67 μL, 0.50 mmol) using CuI (9.5 mg, 0.050 mmol), L1 (10.5 μL, 0.985 mmol), K<sub>2</sub>CO<sub>3</sub> (140 mg, 1.0 mmol), and 200 mg activated 5 Å molecular sieves in anhydrous toluene (1 mL). **4** was purified by column chromatography using a hexane-EtOAc 90:10 to 50:50 gradient. 100 mg (83% yield) of a cream-colored solid were obtained. Mp: 114-116 °C. <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): δ 12.85 (s, 1H), 9.32 (d, *J* = 2.0 Hz, 1H), 8.96 (dd, *J* = 8.5, 1.1 Hz, 1H), 8.81 (dd, *J* = 4.8, 1.5 Hz, 1H), 8.35 (ddd, *J* = 8.0, 2.3, 1.7

Hz, 1H), 8.00 (dd,  $J = 8.0, 1.6$  Hz, 1H), 7.65 (m, 1H), 7.48 (ddd,  $J = 8.0, 4.8, 0.8$  Hz, 1H), 7.22 (ddd,  $J = 8.5, 7.4, 1.2$  Hz, 1H), 2.75 (s, 3H).  $^{13}\text{C-NMR}$  (300 MHz,  $\text{CDCl}_3$ ): 203.5, 164.2, 152.6, 149.2, 140.9, 135.5, 134.9, 132.0, 130.3, 123.5, 123.0, 121.9, 120.7, 28.6. IR (neat,  $\text{cm}^{-1}$ ): 3153, 2919, 1678, 1649, 1610, 1588, 1527, 1454, 1420, 1361, 1316, 1252, 1172, 1112, 1022, 963, 896, 827, 758, 717. Anal. calcd. for  $\text{C}_{14}\text{H}_{12}\text{N}_2\text{O}_2$ : C, 69.99; H, 5.03. Found: C, 69.69; H, 5.04.

***N*-(2-Acetyl-phenyl)-picolinamide (5).**<sup>34</sup> Following General Procedure A, picolinamide (73 mg, 0.60 mmol) was coupled with 2-iodoacetophenone (71  $\mu\text{L}$ , 0.50 mmol) using CuI (9.5 mg, 0.050 mmol), L1 (10.5  $\mu\text{L}$ , 0.985 mmol),  $\text{K}_3\text{PO}_4$  (210 mg, 0.99 mmol), and 200 mg activated 5 Å molecular sieves in anhydrous toluene (1 mL). The reaction was heated for 42 h. **5** was purified by column chromatography using a hexane-EtOAc 95:5 to 70:30 gradient. 85 mg (71% yield) of a pale pink solid were obtained. Mp: 109-112 °C (lit mp: 112-112.5 °C).  $^1\text{H-NMR}$  (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  13.53 (s, 1H), 8.99 (d,  $J = 8.4$  Hz, 1H), 8.76 (d,  $J = 4.3$  Hz, 1H), 8.25 (d,  $J = 7.8$  Hz, 1H), 7.92 (d,  $J = 7.8$  Hz, 1H), 7.86 (td,  $J = 7.7, 1.3$  Hz, 1H), 7.58 (t,  $J = 7.4$  Hz, 1H), 7.45 (m, 1H), 7.13 (t,  $J = 7.4$  Hz, 1H), 2.68 (s, 3H).  $^{13}\text{C-NMR}$  (300 MHz,  $\text{CDCl}_3$ ): 202.3, 164.0, 150.5, 148.8, 140.3, 137.5, 134.9, 131.8, 126.5, 123.2, 122.8, 122.8, 121.1, 28.7. IR (neat,  $\text{cm}^{-1}$ ): 3207, 1684, 1656, 1576, 1517, 1451, 1430, 1363, 1312, 1251, 1169, 1111, 1042 997, 961, 900, 818, 757, 693, 610. Anal. calcd. for  $\text{C}_{14}\text{H}_{12}\text{N}_2\text{O}_2$ : C, 69.99; H, 5.03. Found: C, 69.85; H, 5.18.

***N*-(2-Acetyl-phenyl)-2-thiophenecarboxamide (6).**<sup>35</sup> Following General Procedure A, 2-thiophenecarboxamide (76 mg, 0.60 mmol) was coupled with 2-bromoacetophenone (67  $\mu\text{L}$ , 0.50 mmol) using CuI (9.5 mg, 0.050 mmol), L1 (10.5  $\mu\text{L}$ , 0.985 mmol), and  $\text{K}_2\text{CO}_3$  (140 mg, 1.0 mmol) in anhydrous toluene (1 mL). No molecular sieves were utilized in the synthesis of the title compound. **6** was purified by column chromatography using a hexane-EtOAc 98:2 to 90:10 gradient. 100 mg (82% yield) of a cream-colored solid were obtained. Mp: 131-134 °C (lit mp:

129 °C). <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): δ 12.74 (s, 1H), 8.90 (dd, *J* = 8.5, 1.0 Hz, 1H), 7.97 (dd, *J* = 8.0, 1.4 Hz, 1H), 7.85 (dd, *J* = 3.8, 1.1 Hz, 1H), 7.62 (m, 1H), 7.58 (dd, *J* = 5.0, 1.1 Hz, 1H), 7.17 (m, 2H), 2.74 (s, 3H). <sup>13</sup>C-NMR (300 MHz, CDCl<sub>3</sub>): 203.4, 160.7, 141.3, 140.4, 135.4, 132.0, 131.4, 128.8, 128.1, 122.5, 121.5, 120.5, 28.6. IR (neat, cm<sup>-1</sup>): 3208, 3094, 2919, 1661, 1641, 1608, 1587, 1541, 1450, 1354, 1315, 1247, 1166, 1094, 1029, 960, 863, 811, 754, 731, 610. Anal. calcd. for C<sub>13</sub>H<sub>11</sub>NO<sub>2</sub>S: C, 63.65; H, 4.52. Found: C, 63.39; H, 4.40.

***N*-(2-Acetyl-phenyl)-3-thiophenecarboxamide (7).** Following General Procedure A, 3-thiophenecarboxamide (76 mg, 0.60 mmol) was coupled with 2-bromoacetophenone (67 μL, 0.50 mmol) using CuI (9.5 mg, 0.050 mmol), L1 (10.5 μL, 0.985 mmol), K<sub>2</sub>CO<sub>3</sub> (140 mg, 1.0 mmol), and 200 mg activated 5 Å molecular sieves in anhydrous toluene (1 mL). **7** was purified by column chromatography using a hexane-EtOAc 98:2 to 90:10 gradient. 97 mg (79% yield) of a white solid were obtained. Mp: 90-93 °C. <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): δ 12.63 (s, 1H), 8.93 (dd, *J* = 8.5, 1.1 Hz, 1H), 8.16 (dd, *J* = 3.0, 1.4 Hz, 1H), 7.97 (dd, *J* = 8.0, 1.5 Hz, 1H), 7.69 (dd, *J* = 5.1, 1.3 Hz, 1H), 7.62 (m, 1H), 7.41 (dd, *J* = 5.1, 3.0 Hz, 1H), 7.16 (ddd, *J* = 8.5, 7.3, 1.2 Hz, 1H), 2.73 (s, 3H). <sup>13</sup>C-NMR (300 MHz, CDCl<sub>3</sub>): 203.4, 161.6, 141.5, 138.4, 135.5, 132.0, 129.6, 126.8, 126.5, 122.4, 121.6, 120.6, 28.7. IR (neat, cm<sup>-1</sup>): 3218, 3110, 2924, 1677, 1650, 1607, 1585, 1531, 1451, 1358, 1314, 1254, 1207, 1166, 1102, 1072, 1021, 961, 865, 838, 818, 757, 741, 610. Anal. calcd. for C<sub>13</sub>H<sub>11</sub>NO<sub>2</sub>S: C, 63.65; H, 4.52. Found: C, 63.58; H, 4.41.

***N*-(6-Acetyl-3-fluoro-phenyl)-benzamide (8).** Following General Procedure A, benzamide (76 mg, 0.63 mmol) was coupled with 2-bromo-4-fluoroacetophenone (109 mg, 0.502 mmol) using CuI (9.5 mg, 0.050 mmol), L1 (10.5 μL, 0.985 mmol), K<sub>2</sub>CO<sub>3</sub> (140 mg, 1.0 mmol), and 200 mg activated 5 Å molecular sieves in anhydrous toluene (1 mL). **8** was purified by column chromatography using a hexane-EtOAc 95:5 to 90:10 gradient. 101 mg (79% yield) of a white

solid were obtained. Mp: 123-126 °C. <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): δ 12.91 (s, 1H), 8.78 (dd, *J* = 12.1, 2.6 Hz, 1H), 8.05 (m, 2H), 7.94 (dd, *J* = 8.9, 6.3 Hz, 1H), 7.55 (m, 3H), 6.81 (m, 1H), 2.67 (s, 3H). <sup>13</sup>C-NMR (300 MHz, CDCl<sub>3</sub>): 202.0, 166.5 (d, *J*<sub>CF</sub> = 255 Hz), 166.2, 144.0 (d, *J*<sub>CF</sub> = 13 Hz), 134.4 (d, *J*<sub>CF</sub> = 11 Hz), 132.4, 130.2, 129.0, 127.6, 118.5 (d, *J*<sub>CF</sub> = 3 Hz), 109.8 (d, *J*<sub>CF</sub> = 23 Hz), 107.8 (d, *J*<sub>CF</sub> = 28 Hz), 28.6. IR (neat, cm<sup>-1</sup>): 3175, 1678, 1644, 1602, 1536, 1495, 1361, 1318, 1264, 1250, 1134, 992, 873, 806, 763, 706. Anal. calcd. for C<sub>15</sub>H<sub>12</sub>FNO<sub>2</sub>: C, 70.03; H, 4.70. Found: C, 69.86; H, 4.49.

***N*-(6-Acetyl-3-fluoro-phenyl)-2-chlorobenzamide (9)**. An oven-dried resealable test tube with a Teflon stir bar was charged with CuI (9.5 mg, 0.050 mmol) and NaI (150 mg, 1.0 mmol). The test tube was covered with a rubber septum and evacuated and refilled with argon three times through a syringe needle. Under argon, 2-bromo-4-fluoroacetophenone (109 mg, 0.502 mmol), *N,N'*-dimethylethylenediamine (L1) (10.5 μL, 0.985 mmol), and toluene (1 mL) were each added *via* syringe. The rubber septum was then removed and quickly replaced with a Teflon screw-cap. The test tube was then placed in a preheated oil bath, at 110 °C. The reaction was heated with stirring for 24 h at which point it was cooled to room temperature. Next, 2-chlorobenzamide (93 mg, 0.60 mmol) and K<sub>3</sub>PO<sub>4</sub> (210 mg, 0.99 mmol) were added quickly to the reaction mixture. The test tube was re-capped and the reaction was heated with stirring in the oil bath at 110 °C. After 24 h, the reaction was cooled to room temperature. The reaction mixture was partitioned between ethyl acetate and water and the organic layer was extracted. A second portion of ethyl acetate was used to wash the water layer and was extracted and combined with the first layer. The organic layers were dried over magnesium sulfate, filtered, and concentrated *in vacuo* to remove solvent. **9** was purified by column chromatography with a hexane-EtOAc 95:5 to 90:10 gradient. 97 mg (66% yield) of a beige solid were obtained. Mp: 105-108 °C. <sup>1</sup>H-

NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  12.42 (s, 1H), 8.74 (dd,  $J = 11.9, 2.6$  Hz, 1H), 7.95 (dd,  $J = 8.9, 6.3$  Hz, 1H), 7.62 (dd,  $J = 7.5, 1.8$  Hz, 1H), 7.41 (m, 3H), 6.85 (dd,  $J = 10.0, 7.4, 2.6$  Hz, 1H), 2.63 (s, 3H). <sup>13</sup>C-NMR (300 MHz, CDCl<sub>3</sub>): 201.6, 166.4 (d,  $J_{CF} = 255$  Hz), 166.2, 143.2 (d,  $J_{CF} = 13$  Hz), 135.8, 134.3 (d,  $J_{CF} = 11$  Hz), 131.8, 131.4, 130.8, 129.4, 127.3, 118.8 (d,  $J_{CF} = 3$  Hz), 110.3 (d,  $J_{CF} = 22$  Hz), 108.1 (d,  $J_{CF} = 28$  Hz), 28.7. IR (neat, cm<sup>-1</sup>): 3113, 1691, 1655, 1592, 1524, 1449, 1359, 1317, 1291, 1248, 1171, 1129, 1104, 1047, 993, 956, 871, 805, 784, 744, 715. Anal. calcd. for C<sub>15</sub>H<sub>11</sub>ClFNO<sub>2</sub>: C, 61.76; H, 3.80. Found: C, 61.55; H, 3.77.

***N*-(6-Acetyl-3-fluoro-phenyl)-nicotinamide (10)**. Following General Procedure A, nicotinamide (73 mg, 0.60 mmol) was coupled with 2-bromo-4-fluoroacetophenone (109 mg, 0.502 mmol) using CuI (9.5 mg, 0.050 mmol), L1 (10.5  $\mu$ L, 0.985 mmol), K<sub>2</sub>CO<sub>3</sub> (140 mg, 1.0 mmol), and 200 mg activated 5 Å molecular sieves in anhydrous toluene (1 mL). **10** was purified by column chromatography using a hexane-EtOAc 95:5 to 50:50 gradient. 97 mg (75% yield) of a white solid were obtained. Mp: 165-167 °C. <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  13.04 (s, 1H), 9.30 (s, br, 1H), 8.81 (s, br, 1H), 8.74 (dd,  $J = 11.9, 2.7$  Hz, 1H), 8.32 (d,  $J = 8.0$  Hz, 1H), 7.99 (dd,  $J = 8.9, 6.2$  Hz, 1H), 7.47 (dd,  $J = 7.7, 4.7$  Hz, 1H), 6.87 (ddd,  $J = 10.0, 7.4, 2.6$  Hz, 1H), 2.70 (s, 3H). <sup>13</sup>C-NMR (300 MHz, CDCl<sub>3</sub>): 203.2, 166.5 (d,  $J_{CF} = 256$  Hz), 164.5, 153.0, 149.2, 143.6 (d,  $J_{CF} = 13$  Hz), 135.0, 134.5 (d,  $J_{CF} = 11$  Hz), 130.0, 123.7, 118.6 (d,  $J_{CF} = 3$  Hz), 110.3 (d,  $J_{CF} = 23$  Hz), 108.0 (d,  $J_{CF} = 28$  Hz), 28.7. IR (neat, cm<sup>-1</sup>): 3116, 2921, 1687, 1651, 1606, 1589, 1532, 1460, 1419, 1368, 1320, 1299, 1278, 1261, 1251, 1169, 1143, 1110, 1025, 994, 960, 882, 863, 824, 811, 779, 765, 718. Anal. calcd. for C<sub>14</sub>H<sub>11</sub>FN<sub>2</sub>O<sub>2</sub>: C, 65.11; H, 4.29. Found: C, 65.01; H, 4.10.

***N*-(4-Methoxy-6-propioyl-phenyl)-3-chlorobenzamide (11)**. Following General Procedure A, 3-chlorobenzamide (93 mg, 0.60 mmol) was coupled with 2-bromo-5-methoxypropiophenone

(122 mg, 0.502 mmol) using CuI (9.5 mg, 0.050 mmol), L1 (10.5  $\mu$ L, 0.985 mmol), K<sub>2</sub>CO<sub>3</sub> (140 mg, 1.0 mmol), and 200 mg activated 5 Å molecular sieves in anhydrous toluene (1 mL). **11** was purified by column chromatography using a hexane-EtOAc 95:5 to 90:10 gradient. 107 mg (68% yield) of a pale yellow solid were obtained. Mp: 112-114 °C. <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  12.43 (s, 1H), 8.85 (d,  $J$  = 9.2 Hz, 1H), 8.04 (s, 1H), 7.91 (d,  $J$  = 7.6 Hz, 1H), 7.49 (m, 3H), 7.18 (dd,  $J$  = 9.2, 3.0 Hz, 1H), 3.86 (s, 3H), 3.08 (q,  $J$  = 7.2 Hz, 2H), 1.25 (t,  $J$  = 7.2 Hz, 3H). <sup>13</sup>C-NMR (300 MHz, CDCl<sub>3</sub>): 205.5, 164.2, 154.6, 136.8, 135.1, 134.4, 131.8, 130.1, 128.1, 125.1, 122.9, 122.4, 119.9, 116.1, 55.7, 33.3, 8.6. IR (neat, cm<sup>-1</sup>): 3221, 3087, 2986, 2968, 2947, 2915, 2838, 1668, 1651, 1642, 1615, 1572, 1531, 1454, 1423, 1383, 1320, 1291, 1265, 1252, 1195, 1176, 1050, 973, 836, 817, 730. Anal. calcd. for C<sub>17</sub>H<sub>16</sub>ClNO<sub>3</sub>: C, 64.26; H, 5.08. Found: C, 64.07; H, 5.02.

***N*-(4-Methoxy-6-propioyl-phenyl)-2-thiophenecarboxamide (12)**. Following General Procedure A, 2-thiophenecarboxamide (76 mg, 0.60 mmol) was coupled with 2-bromo-5-methoxypropiophenone (122 mg, 0.502 mmol) using CuI (9.5 mg, 0.050 mmol), L1 (10.5  $\mu$ L, 0.985 mmol), K<sub>2</sub>CO<sub>3</sub> (140 mg, 1.0 mmol), and 200 mg activated 5 Å molecular sieves in anhydrous toluene (1 mL). **12** was purified by column chromatography using a hexane-EtOAc 95:5 to 90:10 gradient. 107 mg (74% yield) of a yellow solid were obtained. Mp: 153-155 °C. <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  12.45 (s, 1H), 8.81 (d,  $J$  = 9.2 Hz, 1H), 7.82 (dd,  $J$  = 3.8, 1.1 Hz, 1H), 7.56 (d,  $J$  = 5.0, 1.1 Hz, 1H), 7.46 (d,  $J$  = 2.9 Hz, 1H), 7.17 (m, 2H), 3.86 (s, 3H), 3.10 (q,  $J$  = 7.2 Hz, 2H), 1.26 (t,  $J$  = 7.2 Hz, 3H). <sup>13</sup>C-NMR (300 MHz, CDCl<sub>3</sub>): 205.5, 160.4, 154.4, 140.7, 134.6, 131.0, 128.4, 128.0, 122.5, 122.2, 120.1, 116.0, 55.7, 33.3, 8.5. IR (neat, cm<sup>-1</sup>): 3216, 2983, 2911, 2830, 1643, 1616, 1595, 1521, 1420, 1352, 1314, 1287, 1261, 1192, 1175,

1056, 1044, 971, 826, 729. Anal. calcd. for  $C_{15}H_{15}NO_3S$ : C, 62.26; H, 5.23. Found: C, 62.06; H, 5.20.

***N*-(2-Acetyl-phenyl)-cinnamamide (13).**<sup>36</sup> Following General Procedure A, cinnamamide (88 mg, 0.60 mmol) was coupled with 2-bromoacetophenone (67  $\mu$ L, 0.50 mmol) using CuI (9.5 mg, 0.050 mmol), *rac* trans-1,2-dimethyl-diamino-cyclohexane (**L2**) (15.8  $\mu$ L, 0.100 mmol),  $K_2CO_3$  (140 mg, 1.0 mmol), and 200 mg activated 5 Å molecular sieves in anhydrous toluene (1 mL). The reaction was heated for 25 h. **13** was purified by column chromatography using a hexane-EtOAc 98:2 to 90:10 gradient. 106 mg (80% yield) of a cream-colored solid were obtained. Mp: 90-93 °C (lit mp: 89.5-90.5 °C).  $^1H$ -NMR (400 MHz,  $CDCl_3$ ):  $\delta$  12.06 (s, 1H), 8.92 (d,  $J$  = 8.5 Hz, 1H), 7.94 (dd,  $J$  = 8.0, 1.1 Hz, 1H), 7.76 (d,  $J$  = 15.6 Hz, 1H), 7.61 (m, 3H), 7.41 (m, 3H), 7.16 (t,  $J$  = 7.2 Hz, 1H), 6.64 (d,  $J$  = 15.6 Hz, 1H), 2.71 (s, 3H).  $^{13}C$ -NMR (300 MHz,  $CDCl_3$ ): 203.2, 165.1, 142.4, 141.5, 135.5, 134.8, 132.0, 130.2, 129.1, 128.3, 122.6, 122.3, 121.9, 121.1, 28.9. IR (neat,  $cm^{-1}$ ): 3224, 3109, 3061, 3027, 1685, 1652, 1629, 1606, 1585, 1524, 1358, 1332, 1295, 1248, 1162, 975, 855, 757, 679, 614. Anal. calcd. for  $C_{17}H_{15}NO_2$ : C, 76.96; H, 5.70. Found: C, 76.89; H, 5.65.

***N*-(2-Acetyl-phenyl)-crotonamide (14).** Following General Procedure A, crotonamide (51 mg, 0.60 mmol) was coupled with 2-iodoacetophenone (71  $\mu$ L, 0.50 mmol) using CuI (9.5 mg, 0.050 mmol), **L1** (10.5  $\mu$ L, 0.985 mmol),  $K_3PO_4$  (210 mg, 0.99 mmol), and 200 mg activated 5 Å molecular sieves in anhydrous toluene (1 mL). The reaction was heated at 110 °C for 24 h. **14** was purified by column chromatography using a hexane-EtOAc 98:2 to 90:10 gradient. 73 mg (71% yield) of a beige solid were obtained. Mp: 80-83 °C.  $^1H$ -NMR (400 MHz,  $CDCl_3$ ):  $\delta$  11.84 (s, 1H), 8.85 (dd,  $J$  = 8.5, 1.1 Hz, 1H), 7.92 (dd,  $J$  = 8.0, 1.6 Hz, 1H), 7.57 (m, 1H), 7.12 (ddd,  $J$  = 8.5, 7.4, 1.2 Hz, 1H), 6.99 (dq,  $J$  = 15.3, 6.9 Hz, 1H), 6.04 (dq,  $J$  = 15.3, 1.7 Hz, 1H), 2.69 (s,



3H), 1.94 (dd,  $J = 6.9, 1.7$  Hz, 3H).  $^{13}\text{C}$ -NMR (300 MHz,  $\text{CDCl}_3$ ): 203.0, 165.0, 141.4, 141.3, 135.2, 131.8, 126.9, 122.3, 121.7, 120.8, 28.7, 18.0. IR (neat,  $\text{cm}^{-1}$ ): 3208, 2915, 1686, 1643, 1607, 1585, 1523, 1453, 1358, 1331, 1298, 1286, 1250, 1188, 1166, 960, 928, 825, 757, 675. Anal. calcd. for  $\text{C}_{12}\text{H}_{13}\text{NO}_2$ : C, 70.92; H, 6.45. Found: C, 71.03; H, 6.45.

**1-(2-Acetyl-phenyl)-pyrrolidin-2-one (15).**<sup>37</sup> Following General Procedure A, 2-pyrrolidinone (46  $\mu\text{L}$ , 0.61 mmol) was coupled with 2-bromoacetophenone (67  $\mu\text{L}$ , 0.50 mmol) using CuI (4.8 mg, 0.025 mmol, 5 mol%), L1 (5.3  $\mu\text{L}$ , 0.050 mmol, 10 mol%),  $\text{K}_2\text{CO}_3$  (140 mg, 1.0 mmol), and 200 mg activated 5 Å molecular sieves in anhydrous toluene (1 mL). The reaction was heated at 90 °C for 25 h. **15** was purified by column chromatography using a hexane-EtOAc 50:50 to 0:100 gradient. 87 mg (86% yield) of a white solid were obtained. Mp: 89-91 °C (lit mp: 88-89 °C).  $^1\text{H}$ -NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.57 (dd,  $J = 7.7, 1.6$  Hz, 1H), 7.43 (m, 1H), 7.29 (m, 1H), 7.17 (d,  $J = 7.9$  Hz, 1H), 3.82 (t,  $J = 7$  Hz, 2H), 2.52 (s, 3H), 2.44 (t,  $J = 8$  Hz, 2H), 2.15 (m, 2H).  $^{13}\text{C}$ -NMR (300 MHz,  $\text{CDCl}_3$ ): 200.6, 175.0, 136.8, 135.9, 131.9, 128.2, 126.8, 125.9, 50.9, 31.8, 28.6, 18.8. IR (neat,  $\text{cm}^{-1}$ ): 3361, 2999, 2958, 2902, 1693, 1598, 1575, 1488, 1453, 1402, 1358, 1324, 1257, 1238, 1167, 1146, 1101, 1020, 968, 776, 656. Anal. calcd. for  $\text{C}_{12}\text{H}_{13}\text{NO}_2$ : C, 70.92; H, 6.45. Found: C, 70.86; H, 6.52.

**General Procedure B: Base-promoted Cyclization to 2-Aryl-4-Quinolones.** A resealable oven-dried test tube with Teflon stir bar was charged with *N*-(keto-aryl)amide (1 equiv) obtained in step one and crushed NaOH (3-3.5 equiv). Anhydrous 1,4-dioxane was added *via* syringe such that the reaction mixture was 0.1M in concentration. The test tube was then sealed with a Teflon screw-cap and the reaction was placed in a preheated oil bath at 110 °C. The reaction mixture was stirred for 1-2 h and then removed from the oil bath and allowed to cool to room temperature. The reaction mixture was then dissolved in ethanol and transferred to a round

bottom flask in which it was concentrated *in vacuo* to remove solvent. Next, a small amount of water and a large amount of hexane were added to the flask and the flask was sonicated for approximately two minutes. The biphasic mixture was neutralized to pH ~7 with 1M HCl and saturated NaHCO<sub>3</sub> solutions. Solid precipitated out of the water layer and the heterogeneous mixture was filtered through a Buchner funnel. The solid powder was rinsed with copious amounts of hexane and minimal water. The solid was collected and transferred to a vial with ethanol and concentrated *in vacuo* to remove residual solvent. In some cases, the hexane rinses during filtration did not completely wash away the alkyl residue and the <sup>1</sup>H-NMR showed contamination. Further purification involved a more extensive hexane wash in which hexane was added to the vial containing the compound and the mixture was sonicated. The solid was allowed to settle, and then the hexane was carefully removed *via* pipette. Hexane was added and removed twice more before the product was dried *in vacuo*.

**2-Phenyl-4-quinolone (16).**<sup>17b</sup> Following General Procedure B, **1** (98 mg, 0.41 mmol) was cyclized using NaOH (49 mg, 1.2 mmol) in 1,4-dioxane (4.1 mL). The reaction was heated for 1 h at 110 °C. After work-up and filtration, 87 mg (96% yield) of a beige solid were obtained. Mp: 247-250 °C (ethanol) (lit mp: 254 °C).<sup>12a</sup> <sup>1</sup>H-NMR (400 MHz, CD<sub>3</sub>OD/CDCl<sub>3</sub>): δ 8.26 (d, *J* = 8.1 Hz, 1H), 7.69 (m, 4H), 7.52 (m, 3H), 7.38 (m, 1H), 6.56 (s, 1H). <sup>13</sup>C-NMR (400 MHz, CD<sub>3</sub>OD/CDCl<sub>3</sub>): 180.3, 153.0, 141.5, 135.0, 133.3, 131.6, 129.9, 128.2, 125.7, 125.4, 125.1, 119.4, 108.4. IR (neat, cm<sup>-1</sup>): 3067, 2962, 1635, 1594, 1581, 1546, 1502, 1472, 1450, 1431, 1355, 1320, 1255, 1139, 839, 798, 771, 753, 689, 670.

**2-(3'-Chlorophenyl)-4-quinolone (17).** Following General Procedure B, **2** (107 mg, 0.39 mmol) was cyclized using NaOH (47 mg, 1.2 mmol) in 1,4-dioxane (3.9 mL). The reaction was heated for 1 h at 110 °C. After work-up and filtration, 96 mg (96% yield) of a cream-colored

solid were obtained. Mp: >260 °C. <sup>1</sup>H-NMR (400 MHz, CD<sub>3</sub>OD/CDCl<sub>3</sub>): δ 8.26 (m, 1H), 7.76 (m, 1H), 7.67 (m, 3H), 7.50 (m, 2H), 7.40 (m, 1H), 6.55 (s, 1H). <sup>13</sup>C-NMR (500 MHz, CD<sub>3</sub>OD/CDCl<sub>3</sub>): 180.4, 151.4, 141.6, 137.0, 135.9, 133.5, 131.5, 131.4, 128.3, 126.7, 125.8, 125.6, 125.3, 119.5, 108.7. IR (neat, cm<sup>-1</sup>): 2193, 1604, 1572, 1558, 1503, 1445, 1350, 841, 769, 757, 705.

**2-(4'-Pyridyl)-4-quinolone (18).**<sup>9h</sup> Following General Procedure B, **3** (63 mg, 0.26 mmol) was cyclized using NaOH (31 mg, 0.78 mmol) in 1,4-dioxane (2.6 mL). The reaction was heated for 2 h at 110 °C. After work-up and filtration, 52 mg (90% yield) of a beige solid were obtained. Mp: >260 °C. <sup>1</sup>H-NMR (400 MHz, CD<sub>3</sub>OD/CDCl<sub>3</sub>): δ 8.71 (d, *J* = 5.0 Hz, 2H), 8.27 (dt, *J* = 8.2, 1.1 Hz, 1H), 7.70 (m, 4H), 7.39 (m, 1H), 6.60 (s, 1H). <sup>13</sup>C-NMR (500 MHz, CD<sub>3</sub>OD/CDCl<sub>3</sub>): 180.1, 150.6, 149.2, 143.2, 141.5, 133.5, 125.7, 125.6, 125.3, 122.8, 119.4, 109.0. IR (neat, cm<sup>-1</sup>): 3066, 2968, 1635, 1591, 1567, 1536, 1506, 1444, 1358, 1259, 1143, 821, 796, 769, 675.

**2-(3'-Pyridyl)-4-quinolone (19).** Following General Procedure B, **4** (81 mg, 0.34 mmol) was cyclized using NaOH (41 mg, 1.0 mmol) in 1,4-dioxane (3.4 mL). The reaction was heated for 1 h at 110 °C. After work-up and filtration, 66 mg (88% yield) of a beige solid were obtained. Mp: >260 °C. <sup>1</sup>H-NMR (400 MHz, CD<sub>3</sub>OD/CDCl<sub>3</sub>): δ 8.90 (dd, *J* = 2.4, 0.8 Hz, 1H), 8.68 (dd, *J* = 4.9, 1.6 Hz, 1H), 8.28 (m, 1H), 8.13 (ddd, *J* = 8.0, 2.4, 1.6 Hz, 1H), 7.66 (m, 2H), 7.55 (ddd, *J* = 8.0, 4.9, 0.8 Hz, 1H), 7.40 (m, 1H), 6.54 (s, 1H). <sup>13</sup>C-NMR (500 MHz, CD<sub>3</sub>OD/CDCl<sub>3</sub>): 180.1, 151.5, 149.2, 148.3, 141.4, 136.6, 133.4, 131.5, 125.8, 125.5, 125.2, 125.0, 119.2, 109.0. IR (neat, cm<sup>-1</sup>): 3090, 2966, 1637, 1602, 1578, 1548, 1509, 1442, 1384, 1356, 1024, 801, 749, 704.

**2-(2'-Pyridyl)-4-quinolone (20).**<sup>15</sup> Following General Procedure B, **5** (89 mg, 0.37 mmol) was cyclized using NaOH (44 mg, 1.1 mmol) in 1,4-dioxane (3.7 mL). The reaction was heated for 1 h at 110 °C. After work-up and filtration, 71 mg (86% yield) of a beige solid were obtained.

Decomposition: 232-234 °C (ethanol). <sup>1</sup>H-NMR (400 MHz, CD<sub>3</sub>OD/CDCl<sub>3</sub>): δ 8.77 (ddd, *J* = 4.8, 1.7, 1.0 Hz, 1H), 8.27 (ddd, *J* = 8.3, 1.5, 0.6 Hz, 1H), 8.09 (d, *J* = 8.1 Hz, 1H), 7.97 (td, *J* = 7.6, 1.8 Hz, 1H), 7.78 (ddd, *J* = 8.5, 1.1, 0.6 Hz, 1H), 7.71 (m, 1H), 7.50 (ddd, *J* = 7.6, 6.9, 1.2 Hz, 1H), 7.41 (ddd, *J* = 8.2, 6.9, 1.2 Hz, 1H), 6.98 (s, 1H). <sup>13</sup>C-NMR (500 MHz, CD<sub>3</sub>OD/CDCl<sub>3</sub>): 181.0, 150.2, 149.8, 147.7, 140.7, 138.7, 133.6, 126.4, 125.9, 125.8, 125.2, 122.3, 119.7, 106.6. IR (neat, cm<sup>-1</sup>): 3063, 1627, 1603, 1573, 1516, 1477, 1384, 1355, 1321, 1254, 1138, 1022, 995, 781, 760, 692. Anal. calcd. for C<sub>14</sub>H<sub>10</sub>N<sub>2</sub>O: C, 75.66; H, 4.54. Found: C, 75.45; H, 4.53.

**2-(2'-Thiophenyl)-4-quinolone (21).**<sup>9a</sup> Following General Procedure B, **6** (97 mg, 0.40 mmol) was cyclized using NaOH (48 mg, 1.2 mmol) in 1,4-dioxane (4.0 mL). The reaction was heated for 1 h at 110 °C. After work-up, filtration, and a hexane wash, 88 mg (97% yield) of a beige solid were obtained. Mp: >260 °C (lit mp: >300 °C).<sup>21d</sup> <sup>1</sup>H-NMR (400 MHz, CD<sub>3</sub>OD/CDCl<sub>3</sub>): δ 8.22 (ddd, *J* = 8.2, 1.4, 0.6 Hz, 1H), 7.76 (dd, *J* = 3.8, 1.1 Hz, 1H), 7.66 (m, 2H), 7.57 (dd, *J* = 5.1, 1.1 Hz, 1H), 7.36 (ddd, *J* = 8.1, 6.7, 1.4 Hz, 1H), 7.19 (dd, *J* = 5.1, 3.8 Hz, 1H), 6.60 (s, 1H). <sup>13</sup>C-NMR (500 MHz, CD<sub>3</sub>OD/CDCl<sub>3</sub>): 179.9, 146.0, 141.1, 136.8, 133.2, 130.0, 129.1, 128.5, 125.6, 125.3, 124.8, 118.9, 107.3. IR (neat, cm<sup>-1</sup>): 3058, 2184, 1598, 1557, 1503, 1443, 1347, 1256, 1136, 857, 824, 768, 756, 697.

**2-(3'-Thiophenyl)-4-quinolone (22).** Following General Procedure B, **7** (67 mg, 0.27 mmol) was cyclized using NaOH (33 mg, 0.83 mmol) in 1,4-dioxane (2.7 mL). The reaction was heated for 2 h at 110 °C. After work-up and filtration, 57 mg (92% yield) of a beige solid were obtained. Mp: >260 °C (CDCl<sub>3</sub>/CD<sub>3</sub>OD). <sup>1</sup>H-NMR (400 MHz, CD<sub>3</sub>OD/CDCl<sub>3</sub>): δ 8.23 (d, *J* = 8.0 Hz, 1H), 8.01 (s, 1H), 7.63 (m, 2H), 7.55-7.33 (m, 3H), 6.61 (s, 1H). <sup>13</sup>C-NMR (500 MHz, CD<sub>3</sub>OD/CDCl<sub>3</sub>): 180.7, 147.8, 141.6, 136.2, 133.5, 128.6, 127.2, 126.9, 125.9, 125.7, 125.2,

119.4, 107.6. IR (neat,  $\text{cm}^{-1}$ ): 3069, 2926, 1633, 1593, 1552, 1508, 1470, 1440, 1428, 1369, 1350, 1313, 1142, 1022, 830, 757, 694.

**7-Fluoro-2-phenyl-4-quinolone (23).**<sup>9f</sup> Following General Procedure B, **8** (76 mg, 0.29 mmol) was cyclized using NaOH (35 mg, 0.88 mmol) in 1,4-dioxane (2.9 mL). The reaction was heated for 2 h at 110 °C. After work-up and filtration, 63 mg (89% yield) of a cream-colored solid were obtained. Mp: >260 °C. <sup>1</sup>H-NMR (400 MHz,  $\text{CD}_3\text{OD}/\text{CDCl}_3$ ):  $\delta$  8.27 (dd,  $J = 9.1, 6.1$  Hz, 1H), 7.72 (m, 2H), 7.52 (m, 3H), 7.36 (dd,  $J = 9.8, 2.4$  Hz, 1H), 7.10 (ddd,  $J = 10.7, 8.3, 2.4$  Hz, 1H), 6.53 (s, 1H). <sup>13</sup>C-NMR (500 MHz,  $\text{CD}_3\text{OD}/\text{CDCl}_3/\text{CD}_2\text{Cl}_2$ ): 179.8, 166.1 (d,  $J_{\text{CF}} = 252$  Hz), 153.6, 143.1 (d,  $J_{\text{CF}} = 13$  Hz), 134.9, 131.7, 130.0, 129.0 (d,  $J_{\text{CF}} = 10$  Hz), 128.2, 122.4 (d,  $J_{\text{CF}} = 1.7$  Hz), 114.1 (d,  $J_{\text{CF}} = 24$  Hz), 108.6, 104.6 (d,  $J_{\text{CF}} = 25$  Hz). IR (neat,  $\text{cm}^{-1}$ ): 3255, 3159, 3117, 3082, 3005, 1641, 1602, 1583, 1542, 1509, 1469, 1425, 1367, 1295, 1253, 1162, 1132, 1092, 869, 840, 816, 771, 744, 696.

**2-(2'-Chlorophenyl)-7-fluoro-4-quinolone (24).** Following General Procedure B, **9** (73 mg, 0.25 mmol) was cyclized using NaOH (30 mg, 0.75 mmol) in 1,4-dioxane (2.5 mL). The reaction was heated for 2 h at 110 °C. After work-up and filtration, 50 mg (73% yield) of a beige solid were obtained. Decomposition: 252-256 °C (ethanol). <sup>1</sup>H-NMR (400 MHz,  $\text{CD}_3\text{OD}/\text{CDCl}_3$ ):  $\delta$  8.30 (dd,  $J = 9.0, 6.0$  Hz, 1H), 7.53 (m, 1H), 7.44 (m, 3H), 7.22 (dd,  $J = 9.6, 2.4$  Hz, 1H), 7.11 (ddd,  $J = 10.8, 8.2, 2.1$  Hz, 1H), 6.31 (s, 1H). <sup>13</sup>C-NMR (500 MHz,  $\text{CD}_3\text{OD}/\text{CDCl}_3$ ): 179.4, 165.8 (d,  $J_{\text{CF}} = 252$  Hz), 150.9, 142.4 (d,  $J_{\text{CF}} = 13$  Hz), 134.2, 133.2, 132.1, 131.3, 130.8, 128.9 (d,  $J_{\text{CF}} = 11$  Hz), 127.8, 122.2, 114.1 (d,  $J_{\text{CF}} = 24$  Hz), 111.1, 104.2 (d,  $J_{\text{CF}} = 25$  Hz). IR (neat,  $\text{cm}^{-1}$ ): 3070, 1642, 1606, 1589, 1551, 1513, 1462, 1259, 1162, 1129, 966, 873, 822, 753, 732.

**7-Fluoro-2-(3'-pyridyl)-4-quinolone (25).** Following General Procedure B, **10** (85 mg, 0.33 mmol) was cyclized using NaOH (40 mg, 1.0 mmol) in 1,4-dioxane (3.3 mL). The reaction was

heated for 1 h at 110 °C. After work-up and filtration, further purification was needed so a hexane wash was performed. Upon drying, 87 mg (96% yield) of a beige solid were obtained. Mp: >260 °C (CDCl<sub>3</sub>/CD<sub>3</sub>OD). <sup>1</sup>H-NMR (400 MHz, CD<sub>3</sub>OD/CDCl<sub>3</sub>): δ 8.93 (s, br, 1H), 8.72 (s, br, 1H), 8.29 (dd, *J* = 9.0, 6.0 Hz, 1H), 8.14 (d, *J* = 8.1 Hz, 1H), 7.58 (s, br, 1H), 7.34 (dd, *J* = 9.6, 2.4 Hz, 1H), 7.13 (ddd, *J* = 10.7, 8.3, 2.4 Hz, 1H), 6.52 (s, 1H). <sup>13</sup>C-NMR (500 MHz, CD<sub>3</sub>OD/CDCl<sub>3</sub>): 179.4, 166.1 (d, *J*<sub>CF</sub> = 252 Hz), 151.7, 150.2, 148.4, 143.5, 136.7, 131.8, 129.0 (d, *J*<sub>CF</sub> = 10 Hz), 125.2, 122.5 (d, *J*<sub>CF</sub> = 1.2 Hz), 114.4 (d, *J*<sub>CF</sub> = 24 Hz), 109.2, 104.8 (d, *J*<sub>CF</sub> = 25 Hz). IR (neat, cm<sup>-1</sup>): 3079, 2921, 2306, 2266, 1636, 1605, 1579, 1568, 1543, 1515, 1467, 1427, 1259, 1213, 1090, 852, 805, 703.

**2-(3'-Chlorophenyl)-6-methoxy-3-methyl-4-quinolone (26).** Following General Procedure B, **11** (66 mg, 0.21 mmol) was cyclized using NaOH (29 mg, 0.73 mmol) in 1,4-dioxane (2.1 mL). The reaction was heated for 2 h at 110 °C. After work-up and filtration, 57 mg (91% yield) of a beige crystalline solid were obtained. Mp: >260 °C. <sup>1</sup>H-NMR (400 MHz, CD<sub>3</sub>OD/CDCl<sub>3</sub>): δ 7.67 (d, *J* = 2.9 Hz, 1H), 7.46 (m, 4H), 7.37 (m, 1H), 7.24 (dd, *J* = 9.1, 2.9 Hz, 1H), 3.90 (s, 3H), 2.03 (s, 3H). <sup>13</sup>C-NMR (500 MHz, CD<sub>3</sub>OD/CDCl<sub>3</sub>): 178.9, 157.5, 148.1, 137.8, 135.4, 135.4, 131.0, 130.5, 129.7, 128.2, 125.3, 124.4, 120.6, 115.9, 104.3, 56.1, 12.8. IR (neat, cm<sup>-1</sup>): 3078, 2957, 1582, 1544, 1501, 1380, 1294, 1229, 1190, 1158, 1097, 1032, 848, 812, 768, 736, 714. Anal. calcd. for C<sub>17</sub>H<sub>14</sub>ClNO<sub>2</sub>: C, 68.12; H, 4.71. Found: C, 68.08; H, 4.73.

**6-Methoxy-3-methyl-2-(2'-thiophenyl)-4-quinolone (27).** Following General Procedure B, **12** (84 mg, 0.29 mmol) was cyclized using NaOH (41 mg, 1.0 mmol) in 1,4-dioxane (2.9 mL). The reaction was heated for 1 h at 110 °C. After work-up and filtration, 73 mg (92% yield) of a pale yellow solid were obtained. Mp: >260 °C (CDCl<sub>3</sub>/CD<sub>3</sub>OD). <sup>1</sup>H-NMR (400 MHz, CD<sub>3</sub>OD/CDCl<sub>3</sub>): δ 7.65 (d, *J* = 2.9 Hz, 1H), 7.58 (dd, *J* = 5.1, 1.2 Hz, 1H), 7.49 (d, *J* = 9.1 Hz,

1H), 7.33 (dd,  $J = 3.6, 1.2$  Hz, 1H), 7.23 (dd,  $J = 9.1, 2.9$  Hz, 1H), 7.18 (dd,  $J = 5.1, 3.6$  Hz, 1H), 3.90 (s, 3H), 2.18 (s, 3H).  $^{13}\text{C}$ -NMR (500 MHz,  $\text{CD}_3\text{OD}/\text{CDCl}_3$ ): 178.9, 157.8, 143.2, 136.1, 135.7, 130.7, 129.4, 128.4, 125.5, 124.6, 120.8, 117.2, 104.4, 56.1, 13.1. IR (neat,  $\text{cm}^{-1}$ ): 2951, 1589, 1541, 1488, 1439, 1375, 1256, 1228, 1161, 1026, 850, 822.7, 768, 708, 692. Anal. calcd. for  $\text{C}_{15}\text{H}_{13}\text{NO}_2\text{S}$ : C, 66.40; H, 4.83. Found (Recrystallized from  $\text{CDCl}_3/\text{CD}_3\text{OD}$ ): C, 66.18; H, 4.74.

**2-Styryl-4-quinolone (28).**<sup>38</sup> Following General Procedure B, **13** (101 mg, 0.38 mmol) was cyclized using NaOH (46 mg, 1.2 mmol) in 1,4-dioxane, (3.8 mL). The reaction was heated for 3 h at 90 °C. After work-up and filtration, 77 mg (82% yield) of an orange-yellow solid were obtained. Mp: >260 °C (lit mp: 279 °C).  $^1\text{H}$ -NMR (400 MHz,  $\text{CD}_3\text{OD}/\text{CDCl}_3$ ):  $\delta$  8.22 (ddd,  $J = 8.2, 1.4, 0.6$  Hz, 1H), 7.58 (m, 5H), 7.38 (m, 4H), 6.96 (d,  $J = 16.5$  Hz, 1H), 6.55 (s, 1H).  $^{13}\text{C}$ -NMR (400 MHz,  $\text{CD}_3\text{OD}/\text{CDCl}_3$ ): 180.0, 149.5, 141.0, 137.5, 136.0, 133.1, 130.3, 129.6, 128.1, 125.6, 125.6, 124.8, 121.5, 118.8, 107.0. IR (neat,  $\text{cm}^{-1}$ ): 3059, 2040, 1621, 1590, 1547, 1494, 1436, 1246, 1138, 959, 752, 686.

**2,3-Dihydro-pyrrolo[1,2-a]quinolin-5(1H)-one (29).**<sup>37</sup> Following General Procedure B, **15** (71 mg, 0.35 mmol) was cyclized using NaOH (49 mg, 1.2 mmol) in 1,4-dioxane (3.5 mL). The reaction was heated for 1 h at 110 °C. After the reaction was cooled to room temperature, it was transferred into a round bottom flask with ethanol. The solvent was removed *in vacuo* and water was added. The solution was neutralized to pH ~7 with 1M HCl and saturated  $\text{NaHCO}_3$  solutions and then the water was removed *in vacuo*. The title compound was purified by silica column chromatography using a EtOAc-MeOH 100:0 to 95:5 gradient. After the product was collected and concentrated, a hexane wash was performed. 60 mg (93% yield) of a beige solid were obtained. Mp: 167-173 °C (lit mp: 173-174°C).  $^1\text{H}$ -NMR (400 MHz,  $\text{CD}_3\text{OD}/\text{CDCl}_3$ ):  $\delta$  8.24 (d,

$J = 8.5, 1.5$  Hz, 1H), 7.64 (ddd,  $J = 8.5, 7.1, 1.5$  Hz, 1H), 7.36 (m, 2H), 6.19 (s, 1H), 4.26 (t,  $J = 7.3$  Hz, 2H), 3.15 (t,  $J = 7.6$  Hz, 2H), 2.10 (m, 2H).  $^{13}\text{C}$ -NMR (400 MHz,  $\text{CD}_3\text{OD}/\text{CDCl}_3$ ): 179.3, 157.8, 139.1, 133.0, 126.5, 125.8, 124.6, 116.7, 105.0, 51.3, 32.4, 21.4. IR (neat,  $\text{cm}^{-1}$ ): 3480 (br), 3388 (br), 2964, 2895, 1625, 1599, 1558, 1503, 1473, 1430, 1310, 1267, 1167, 1151, 1073, 1030, 962, 840, 787, 759, 671, 621.

**2-(1'-Propenyl)-4-quinolone (30).**<sup>39</sup> Following General Procedure B, **14** (84 mg, 0.41 mmol) was cyclized using NaOH (25 mg, 0.63 mmol, 1.5 equiv) in 1,4-dioxane (4.1 mL). The reaction was heated for 1 h at 110 °C. After the reaction was cooled to room temperature, it was transferred into a round bottom flask with ethanol. The solvent was removed *in vacuo* and water was added. The solution was neutralized to pH ~7 with 1M HCl and saturated  $\text{NaHCO}_3$  solutions and then the water was removed *in vacuo*. The title compound was purified by silica column chromatography using a hexane-EtOAc 50:50 to 0:100 gradient. After the product was collected and concentrated, a hexane wash was performed. 42 mg (54% yield) of a pale yellow solid were obtained. Decomposition: 240-244 °C (lit decomposition: 210 °C).  $^1\text{H}$ -NMR (400 MHz,  $\text{CD}_3\text{OD}/\text{CDCl}_3$ ):  $\delta$  8.17 (d,  $J = 7.9$  Hz, 1H), 7.54 (m, 2H), 7.28 (m, 1H), 6.68 (m, 1H), 6.32 (s, 1H), 6.24 (dd,  $J = 15.9, 1.5$  Hz, 1H), 1.91 (dd,  $J = 6.7, 1.4$  Hz, 3H).  $^{13}\text{C}$ -NMR (500 MHz,  $\text{CD}_3\text{OD}/\text{CDCl}_3$ ): 180.0, 149.6, 140.7, 136.4, 132.8, 125.5, 125.4, 125.2, 124.6, 118.7, 106.1, 19.2. IR (neat,  $\text{cm}^{-1}$ ): 3061, 2916, 2773, 2189, 2115, 1596, 1549, 1499, 1442, 1354, 1326, 1249, 1138, 961, 835, 756.

**4-Methyl-3-vinyl-2-quinolone (31).**<sup>40</sup> Following a slight modification of General Procedure B, **14** (94 mg, 0.46 mmol) was cyclized using  $\text{Cs}_2\text{CO}_3$  (450 mg, 1.4 mmol) in 1,4-dioxane (4.6 mL). The reaction was heated for 24 h at 110 °C. After the reaction was cooled to room temperature, it was transferred into a round bottom flask with ethanol. The solvent was removed *in vacuo* and



water was added. The solution was neutralized to pH ~ 7 with 1M HCl and saturated NaHCO<sub>3</sub> solutions and then the water was removed *in vacuo*. The title compound was purified by silica column chromatography using a hexane-EtOAc 75:25 to 100:0 gradient. After the product was collected and concentrated, a hexane wash was performed. 65 mg (76% yield) of a pale yellow solid were obtained. Decomposition: >150 °C (lit mp: 203-205°C). <sup>1</sup>H-NMR (400 MHz, CD<sub>3</sub>OD/CDCl<sub>3</sub>): δ 7.73 (dd, *J* = 8.2, 0.9 Hz, 1H), 7.44 (m, 1H), 7.28 (dd, *J* = 8.2, 0.7 Hz, 1H), 7.21 (m, 1H), 6.76 (dd, *J* = 17.8, 11.7 Hz, 1H), 5.77 (dd, *J* = 17.8, 2.1 Hz, 1H), 5.64 (dd, *J* = 11.7, 2.1 Hz, 1H), 2.55 (s, 3H). <sup>13</sup>C-NMR (400 MHz, CD<sub>3</sub>OD/CDCl<sub>3</sub>): 163.3, 145.3, 137.4, 131.2, 130.7, 128.3, 125.7, 123.3, 122.5, 121.7, 116.3, 16.3. IR (neat, cm<sup>-1</sup>): 2944, 2845, 1648, 1603, 1551, 1503, 1431, 1380, 1270, 919, 747, 664. Anal. calcd. for C<sub>12</sub>H<sub>11</sub>NO: C, 77.81; H, 5.99. Found: C: 77.70, H: 5.96.

***N*-(2-Acetyl-phenyl)-*n*-hexanamide (32).** Following General Procedure A, hexanamide (138 mg, 1.20 mmol) was coupled with 2-iodoacetophenone (141 mL, 1.00 mmol) using CuI (9.5 mg, 0.050 mmol), L1 (10.5 μL, 0.100 mmol), K<sub>3</sub>PO<sub>4</sub> (425 mg, 2.0 mmol), and 400 mg activated 5 Å molecular sieves in anhydrous toluene (2 mL). The title compound was purified by column chromatography using a 5-10% ethyl acetate/hexane gradient. 187 mg (80% yield) of a clear, yellow oil were obtained. <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): δ 11.68 (s, 1H), 8.73 (dd, *J* = 8.5, 1.1 Hz, 1H), 7.82 (dd, *J* = 8.0, 1.5 Hz, 1H), 7.47 (m, 1H), 7.03 (m, 1H), 2.60 (s, 3H), 2.37 (t, *J* = 7.4 Hz, 2H), 1.70 (m, 2H), 1.32 (m, 4H), 0.86 (m, 3H). <sup>13</sup>C-NMR (300 MHz, CDCl<sub>3</sub>): 202.8, 172.7, 141.2, 135.1, 131.7, 122.1, 121.6, 120.6, 38.7, 31.4, 31.4, 28.6, 25.2, 22.4, 22.4, 14.0. IR (neat, cm<sup>-1</sup>): 3253, 2957, 2931, 2861, 1699, 1653, 1607, 1585, 1521, 1451, 1360, 1311, 1298, 1248, 1163, 1092, 1022, 962, 756, 606. Anal. calcd. for C<sub>14</sub>H<sub>19</sub>NO<sub>2</sub>: C, 72.07; H, 8.21. Found: C, 72.23; H, 8.26.

**3-*n*-Butyl-4-methyl-2-quinolone (33)**<sup>41</sup> and **2-*n*-Pentyl-4-quinolone (34)**.<sup>42</sup> Following General Procedure B, **32** (82 mg, 0.35 mmol) was cyclized using NaOH (42 mg, 3 equiv.) in 1,4-dioxane (3.5 mL). The reaction was heated for 1 h at 110 °C. After the reaction was cooled to room temperature, ethanol was added to dissolve all solid and the reaction mixture was loaded directly onto a Biotage samplet. The samplet was dried with gentle heating. The title compounds were purified by silica column chromatography using a hexane-EtOAc 75:25 to 0:100 gradient followed by a EtOAc-MeOH 100:0 to 95:5 gradient. **33** eluted faster than **34** under these conditions. After the products were collected and concentrated, hexane washes were performed on both compounds. 17 mg (23% yield) of **33** were obtained as a white solid. Mp: 171-173 °C (lit mp: 170-171 °C). <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): δ 11.99 (s, br, 1H), 7.70 (dd, *J* = 8.2, 0.9 Hz, 1H), 7.46 (m, 1H), 7.38 (m, 1H), 7.21 (m, 1H), 2.83 (t, *J* = 7.3 Hz, 2H), 2.51 (s, 3H), 1.52 (m, 4H), 0.99 (t, *J* = 7.2 Hz, 3H). <sup>13</sup>C-NMR (400 MHz, CDCl<sub>3</sub>): 164.1, 143.2, 137.0, 131.9, 129.3, 124.4, 122.3, 121.3, 116.2, 31.5, 26.9, 23.2, 15.3, 14.3. IR (neat, cm<sup>-1</sup>): 2946, 2860, 1654, 1611, 1562, 1503, 1428, 1394, 1274, 1182, 1158, 1097, 1032, 905, 747, 706, 667, 613. 37 mg (49% yield) of **34** were obtained as a white solid. Mp: 142-145 °C (lit mp: 141-142 °C). <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): δ 13.02 (s, 1H), 8.38 (d, *J* = 8.0 Hz, 1H), 7.88 (d, *J* = 8.4 Hz, 1H), 7.60 (t, *J* = 7.1 Hz, 1H), 7.35 (t, *J* = 7.5 Hz, 1H), 6.28 (s, 1H), 2.72 (t, *J* = 7.5 Hz, 2H), 1.71 (m, 2H), 1.22 (m, 4H), 0.78 (t, *J* = 6.8 Hz, 3H). <sup>13</sup>C-NMR (400 MHz, CDCl<sub>3</sub>): 179.0, 156.0, 141.0, 131.9, 125.2, 123.8, 119.0, 108.2, 34.5, 31.5, 29.1, 22.5, 14.0. IR (neat, cm<sup>-1</sup>): 3250, 3065, 2956, 2930, 2871, 1639, 1595, 1552, 1505, 1472, 1444, 1355, 1322, 1249, 1176, 1138, 1111, 844, 761, 675.

**General Procedure C: McMurry-Type Coupling to Form Indoles.**<sup>18</sup> In a glove box, TiCl<sub>3</sub> (1.8 mmol, 3.6 equiv.) and Zn powder (3.6 mmol, 7.2 equiv.) were weighed into an oven-dried Schlenk tube with a Teflon-coated stir bar. The Schlenk tube was capped with a rubber septum

and removed from the glove box. Outside of the glove box, the Schlenk tube was evacuated and refilled with Argon twice. While still under a stream of Argon, the rubber septum was removed and the *N*-(keto-aryl)amide (0.5 mmol, 1 equiv.) was added quickly to the Schlenk tube. The Schlenk tube was recapped with the septum and evacuated and refilled with Argon three more times. Anhydrous DME was added *via* syringe and the rubber septum was replaced with a Teflon Schlenk cap. The reaction was placed in a preheated oil bath at 90 °C, and the reaction was heated with stirring for 4-28 h, monitored by TLC. The reaction mixture was allowed to cool to room temperature and filtered through a pad of silica gel with copious amounts of EtOAc. The filtrate was concentrated *in vacuo*, and the crude material was purified *via* silica gel column chromatography using a hexane-EtOAc 100:0 to 92:8 gradient.

**3-Methyl-2-phenylindole (35).**<sup>22</sup> Following General Procedure C, **1** (119.6 mg, 0.50 mmol) underwent an intramolecular coupling using TiCl<sub>3</sub> (280 mg, 1.8 mmol) and Zn powder (235 mg, 3.6 mmol) in DME (6.0 mL). The reaction was heated for 28 h at 90 °C. After filtration and column chromatography, 71 mg (69% yield) of a pale yellow solid were obtained. Mp: 88-92 °C (lit mp. 90-92 °C). <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): δ 8.03 (s, br, 1H), 7.61 (m, 3H), 7.50 (m, 2H), 7.38 (m, 2H), 7.23 (m, 1H), 7.17 (m, 1H), 2.49 (s, 3H). <sup>13</sup>C-NMR (400 MHz, CDCl<sub>3</sub>): 136.1, 134.3, 133.6, 130.3, 129.1, 128.0, 127.6, 122.6, 119.8, 119.3, 111.0, 108.9, 9.9. IR (neat, cm<sup>-1</sup>): 3448, 3421, 3056, 2914, 2862, 1603, 1458, 1445, 1332, 1306, 1235, 1074, 918, 770, 739, 700.

**3-Methyl-2-(3'-thiophenyl)-indole (36).** Following General Procedure C, **7** (122.7 mg, 0.50 mmol) underwent an intramolecular coupling using TiCl<sub>3</sub> (280 mg, 1.8 mmol) and Zn powder (235 mg, 3.6 mmol) in DME (6.0 mL). The reaction was heated for 16 h at 90 °C. After filtration and column chromatography, 75 mg (70% yield) of a beige solid were obtained. Mp: 92-95 °C. <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): δ 7.77 (s, br, 1H), 7.55 (d, *J* = 7.7 Hz, 1H), 7.34 (dd, *J* = 4.6, 3.4

Hz, 1H), 7.24 (m, 3H), 7.13 (m, 3H), 2.39 (s, 3H). <sup>13</sup>C-NMR (400 MHz, CDCl<sub>3</sub>): 135.7, 134.2, 130.0, 130.0, 126.7, 126.3, 122.4, 121.3, 119.7, 119.0, 110.8, 108.6, 9.87. IR (neat, cm<sup>-1</sup>): 3417, 3100, 3056, 2916, 2862, 1461, 1350, 1332, 1291, 1240, 1206, 1153, 1118, 1090, 1025, 1007, 865, 781, 741, 683, 619. Anal. calcd. for C<sub>13</sub>H<sub>11</sub>NS: C, 73.20; H, 5.20. Found: C, 73.33; H, 5.30.

**2,3-Dihydro-9-methyl-1H-pyrrolo[1,2-a]indole (37).**<sup>43</sup> Following General Procedure C, 15 (101.6 mg, 0.50 mmol) underwent an intramolecular coupling using TiCl<sub>3</sub> (280 mg, 1.8 mmol) and Zn powder (235 mg, 3.6 mmol) in DME (6.0 mL). The reaction was heated for 4.5 h at 90 °C. After filtration and column chromatography, 29 mg (34% yield) of a colorless oil were obtained. Note: Title compound readily decomposes even at low temperature. <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): δ 7.54 (d, *J* = 7.4 Hz, 1H), 7.25 (m, 1H), 7.14 (m, 2H), 4.06 (t, *J* = 6.9 Hz, 2H), 2.98 (t, *J* = 7.5 Hz, 2H), 2.63 (m, 2H), 2.32 (s, 3H). <sup>13</sup>C-NMR (400 MHz, CDCl<sub>3</sub>): 141.5, 133.3, 132.7, 120.1, 118.5, 118.5, 109.3, 100.8, 43.7, 28.0, 23.1, 9.2.

**2-Bromo-5-methoxypropiophenone.**<sup>44,45</sup> 2-Bromo-5-methoxybenzoyl chloride (1.91 g, 7.67 mmol) was added to a flame-dried round bottom flask. The flask was covered with a rubber septum and then evacuated and refilled with Argon three times. Anhydrous THF (20 mL) was added *via* syringe and the reaction mixture was cooled to -78 °C. Ethyl magnesium bromide (3M in ether) was added drop-wise over approximately 30 minutes. Then the reaction mixture was allowed to warm to room temperature and was stirred for 20 h at which point saturated ammonium chloride was added. The organic layer was extracted and concentrated. Then it was partitioned between ether and water. The ether layer was extracted and then washed once more with water. The organic layer was dried over MgSO<sub>4</sub>, filtered, and concentrated to dry. The title compound was purified by silica column chromatography using a hexane-EtOAc 100:0 to 90:10 gradient. 1.37 g (74% yield) of a clear, yellow oil were obtained. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ

7.47 (dd,  $J = 8.6, 0.5$  Hz, 1H), 6.85 (m, 2H), 3.81 (s, 3H), 2.93 (q,  $J = 7.2$  Hz, 2H), 1.21 (t,  $J = 7.2$  Hz, 3H).  $^{13}\text{C-NMR}$  (400 MHz,  $\text{CDCl}_3$ ): 204.7, 158.8, 142.6, 134.2, 117.1, 113.6, 108.5, 55.5, 35.9, 8.0. IR (neat,  $\text{cm}^{-1}$ ): 3073, 2977, 2939, 2905, 2840, 1705, 1592, 1569, 1467, 1405, 1345, 1290, 1241, 1198, 1175, 1090, 1051, 1027, 967, 874, 846, 816.

#### IV. References

1. (a) Jiang, L.; Buchwald, S. L. in *Metal-Catalyzed Cross-Coupling Reactions*, 2<sup>nd</sup> ed.; de Meijere, A., Diederich, F., Eds.; Wiley-VCH: Weinheim, 2004; pp 699-760. (b) Hartwig, J. F. *Synlett* **2006**, 9, 1283-1294.
2. Zou, B.; Yuan, Q.; Ma, D. *Angew. Chem. Int. Ed.* **2007**, 46, 2598-2601.
3. Martín, R.; Rodríguez Rivero, M.; Buchwald, S. L. *Angew. Chem. Int. Ed.* **2006**, 45, 7079-7082.
4. Manley, P. J.; Bilodeau, M. T. *Org. Lett.* **2004**, 6, 2433-2435.
5. (a) Ackermann, L. *Org. Lett.* **2005**, 7, 439-442. (b) Tang, Z.-Y.; Hu, Q.-S. *Adv. Synth. Catal.* **2006**, 348, 846-850. (c) Liu, F.; Ma, D. *J. Org. Chem.* **2007**, ASAP.
6. Rodríguez Rivero, M.; Buchwald, S. L. *Org. Lett.* **2007**, 9, 973-976.
7. Pozharskii, A. F.; Soldatenkov, A. T.; Katritzky, A. R. *Heterocycles and Health. in Heterocycles in Life and Society*; John Wiley: Chichester, U.K., 1997; pp 135-164.
8. It is known that 4-quinolines have two tautomeric forms and can be drawn as either the 4-hydroxyquinolines in the enol-form or as 4-quinolones in the keto-form (Scheme 5). Both forms are important in understanding the characterization data and the chemical reactivity of such compounds. However, it is believed that in the solid state, as well as in many solvents, these compounds exist primarily in the keto-form. Therefore, for the purposes of this publication, we will refer to and draw the products as 4-quinolones. For discussions on the tautomerization of hydroxyquinolines: (a) Reitsema, R. H. *Chem. Rev.* **1948**, 43, 43-68. (b) Katritzky, A. R.; Lagowski, J. M. Prototropic Tautomerism of Heteroaromatic Compounds: II. Six-Membered Rings. in *Advances in Heterocyclic Chemistry*, vol. 1; Katritzky, A. R.; Ed.; Academic Press, Inc.: New York, 1963, pp. 339-437. (c) Mphahlele, M. J.; El-Nahas, A. M. *J. Mol. Struct.* **2004**, 688, 129-136.
9. (a) Osawa, T.; Ohta, H.; Akimoto, K.; Harada, K.; Soga, H.; Jinno, Y. 4(1H)quinolone Derivatives. Eur. Patent 0 343 574, 1994. (b) Huang, L.-J.; Hsieh, M.-C.; Teng, C.-M.; Lee, K.-H.; Kuo, S.-C. *Bio. Med. Chem.* **1998**, 6, 1657-1662. (c) Takami, H.; Kishibayashi, N.; Ishii, A.; Kumazawa, T. *Bio. Med. Chem.* **1998**, 6, 2441-2448. (d) Lee, H.-Z.; Lin, W.-C.; Yeh, F.-T.; Wu,

C.-H. *Eur. J. Pharmacol.* **1998**, *354*, 205-213. (e) Jackson, S. P.; Robertson, A. D.; Kenche, V.; Thompson, P.; Prabakaran, H.; Anderson, K.; Abbott, B.; Goncalves, I.; Nesbitt, W.; Schoenwaelder, S.; Saylik, D. Inhibition of Phosphoinositide 3-Kinase Beta. PCT Int. Patent WO 2004/016607, 2004. (f) Llinàs-Brunet, M.; Bailey, M. D.; Ghiro, E.; Gorys, V.; Halmos, T.; Poirier, M.; Rancourt, J.; Goudreau, N. *J. Med. Chem.* **2004**, *47*, 6584-6594. (g) Wu, F. X. H.; Nakajima, S.; Or, Y. S.; Lu, Z.-H.; Sun, Y.; Miao, Z.; Wang, Z. Aza-Peptide Macrocyclic Hepatitis C Serine Protease Inhibitors. PCT Int. Patent WO 2005/010029, 2005. (h) Pal, M.; Khanna, I.; Subramanian, V.; Padakanti, S.; Pillarisetti, S. Heterocyclic and Bicyclic Compounds, Compositions and Methods. PCT Int. Patent WO 2006/058201, 2006. (i) Frutos, R. P.; Haddad, N.; Houpis, I. N.; Johnson, M.; Smith-Keenan, L. L.; Fuchs, V.; Yee, N. K.; Farina, V.; Faucher, A.-M.; Brochu, C.; Haché, B.; Duceppe, J.-S.; Beaulieu, P. *Synthesis* **2006**, *15*, 2563-2567.

10. Selected references on 2-aryl-4-quinolones as antitumor agents: (a) Kuo, S.-C.; Lee, H.-Z.; Juang, J.-P.; Lin, Y.-T.; Wu, T.-S.; Chang, J.-J.; Lednicer, D.; Paull, K. D.; Lin, C. M.; Hamel, E.; Lee, K.-H. *J. Med. Chem.* **1993**, *36*, 1146-1156. (b) Li, L.; Wang, H.-K.; Kuo, S.-C.; Wu, T.-S.; Lednicer, D.; Lin, C. M.; Hamel, E.; Lee, K.-H. *J. Med. Chem.* **1994**, *37*, 1126-1135. (c) Li, L.; Wang, H.-K.; Kuo, S.-C.; Wu, T.-S.; Mauger, A.; Lin, C. M.; Hamel, E.; Lee, K.-H. *J. Med. Chem.* **1994**, *37*, 3400-3407. (d) Sui, Z.; Nguyen, V. N.; Altom, J.; Fernandez, J.; Hilliard, J. J.; Bernstein, J. I.; Barrett, J. F.; Ohemeng, K. A.; *Eur. J. Med. Chem.* **1999**, *34*, 381-387. (e) Xia, Y.; Yang, Z.-Y.; Xia, P.; Hackl, T.; Hamel, E.; Mauger, A.; Wu, J.-H.; Lee, K.-H. *J. Med. Chem.* **2001**, *44*, 3932-3936. (f) Hadjeri, M.; Peiller, E.-L.; Beney, C.; Deka, N.; Lawson, M. A.; Dumontet, C.; Boumendjel, A. *J. Med. Chem.* **2004**, *47*, 4964-4970. (g) Hradil, P.; Krejčí, P.; Hlavác, J.; Wiedermannová, I.; Lycka, A.; Bertolasi, V. *J. Heterocyclic Chem.* **2004**, *41*, 375-379. (h) Lai, Y.-Y.; Hung, L.-J.; Lee, K.-H.; Xiao, Z.; Bastow, K. F.; Yamori, T.; Kuo, S.-C. *Bioorg. Med. Chem.* **2005**, *13*, 265-275. (i) Ferlin, M. G.; Chiarelto, G.; Gasparotto, V.; Via, L. D.; Pezzi, V.; Barzon, L.; Palu, G.; Castagliuolo, I. *J. Med. Chem.* **2005**, *48*, 3417-3427. (j) Gasparotto, V.; Castagliuolo, I.; Chiarelto, G.; Pezzi, V.; Montanaro, D.; Brun, P.; Palu, G.; Viola, G.; Ferlin, M. G. *J. Med. Chem.* **2006**, *49*, 1910-1915.

11. (a) Li, J. J. Conrad-Limpach Reaction in *Name Reactions: A Collection of Detailed Reaction Mechanisms*, 2<sup>nd</sup> ed.; Springer-Verlag: Berlin, 2003; p 81. (b) Niementowski, S. *Ber. Dtsch. Chem. Ges.* **1894**, *27*, 1394-1403.

12. (a) Staskun, B.; Israelstam, S. S. *J. Org. Chem.* **1961**, *26*, 3191-3193. (b) Giardina, G. A. M.; Sarau, H. M.; Farina, C.; Medhurst, A. D.; Grugni, M.; Rveglia, L. F.; Schmidt, D. B.; Rigolio, R.; Luttmann, M.; Vecchiotti, V.; Hay, D. W. P. *J. Med. Chem.* **1997**, *40*, 1794-1807.

13. (a) Dorow, R. L.; Herrinton, P. M.; Hohler, R. A.; Maloney, M. T.; Mauragis, M. A.; McGhee, W. E.; Moeslein, J. A.; Strohbach, J. W.; Veley, M. F. *Org. Process Res. Dev.* **2006**, *10*, 493-499. (b) Zewge, D.; Chem, C.-Y.; Deer, C.; Dormer, P. G.; Hughes, D. L. *J. Org. Chem.* **2007**, ASAP.

14. (a) Fuson, R. C.; Burness, D. M. *J. Am. Chem. Soc.* **1946**, *68*, 1270-1272. (b) Ogata, Y.; Kawasaki, A.; Tsujimura, K. *Tetrahedron* **1971**, *27*, 2765-2770.

15. Son, J. K.; Kim, S. I.; Jahng, Y. *Heterocycles* **2001**, *55*, 1981-1986.

16. (a) Tang, J.; Huang, X. *Synth. Commun.* **2003**, *33*, 3953-3960. (b) Beifuss, U.; Ledderhose, S. *Synlett* **1997**, 313-315. (c) Strekowski, L.; Wydra, R. L.; Cegla, M. T.; Czarny, A.; Harden, D. B.; Patterson, S. E.; Battiste, M. A.; Coxon, J. M. *J. Org. Chem.* **1990**, *55*, 4777-4779.

17. (a) Kalinin, V. N.; Shostakovsky, M. V.; Ponomaryov, A. B. *Tetrahedron Lett.* **1992**, *33*, 373-376. (b) Torii, S.; Okumoto, H.; Xu, L. H.; Sadakane, M.; Shostakovsky, M. V.; Ponomaryov, A. B.; Kalinin, V. N. *Tetrahedron* **1993**, *49*, 6773-6784.

18. Fürstner, A.; Hupperts, A.; Ptock, A.; Janssen, E. *J. Org. Chem.* **1994**, *59*, 5215-5229.

19. Tollari, S.; Cenini, S.; Ragaini, F.; Cassar, L. *J. Chem. Soc., Chem. Commun.* **1994**, 1741-1742.

20. (a) Camps, R. *Chem. Ber.* **1899**, *32*, 3228-3234. (b) Pflum, D. A. Camps Quinolinol Synthesis. in *Name Reactions in Heterocyclic Chemistry*; Li, J. J., Corey, E. J., Eds.; Wiley-Interscience: Hoboken, NJ, 2005; pp 386-389.

21. (a) Clémence, F.; Le Martret, O.; Collard, J. *J. Heterocyclic Chem.* **1984**, *21*, 1345-1353. (b) Dubroeuq, M.-C.; Bains, E. L.; Paris, J.-M.; Marne, V. S.; Renault, C. Quinolyloxyacetamides. U.S. Patent 5017576, 1991. (c) Hadjeri, M.; Mariotte, A.-M.; Boumendjel, A. *Chem. Pharm. Bull.* **2001**, *49*, 1352-1355. (d) Ding, D.; Li, X.; Wang, X.; Du, Y.; Shen, J. *Tetrahedron Lett.* **2006**, *47*, 6997-6999.

22. Fürstner, A.; Jumbam, D. N. *Tetrahedron* **1992**, *48*, 5991-6010.

23. For a review: Fürstner, A.; Bogdanovic, B. *Angew. Chem. Int. Ed. Engl.* **1996**, *35*, 2442-2469.

24. (a) Klapars, A.; Antilla, J. C.; Huang, X.; Buchwald, S. L. *J. Am. Chem. Soc.* **2001**, *123*, 7727-7729. (b) Klapars, A.; Huang, X.; Buchwald, S. L. *J. Am. Chem. Soc.* **2002**, *124*, 7421-7428. (c) Streiter, E. R.; Blackmond, D. G.; Buchwald, S. L. *J. Am. Chem. Soc.* **2005**, *127*, 4120-4121.

25. References indicating catalyst-free amination reactions: (a) Beller, M.; Breindl, C.; Riermeier, T. H.; Tillack, A. *J. Org. Chem.* **2001**, *66*, 1403-1412. (b) Shi, L.; Wang, M.; Fan, C.-A.; Zhang, F.-M.; Tu, Y.-Q. *Org. Lett.* **2003**, *5*, 3515-3517. (c) De Lange, B.; Lambers-Verstappen, M. H.; Schmieder-van de Vondervoort, L.; Sereinig, N.; de Rijk, R.; de Vries, A. H. M.; de Vries, J. G. *Synlett* **2006**, *18*, 3105-3109.

26. (a) Lindley, J. *Tetrahedron* **1984**, *40*, 1433-1456. (b) Nicolaou, K. C.; Boddy, C. N. C.; Natarajan, S.; Yue, T.-Y.; Li, H.; Bräse, Ramanjulu, J. M. *J. Am. Chem. Soc.* **1997**, *119*, 3421-3422. (c) Cai, Q.; Zou, B.; Ma, D. *Angew. Chem. Int. Ed.* **2006**, *45*, 1276-1279.


27. Aryl iodides were found to be better starting materials for the more difficult Cu-catalyzed amidation reactions of 2-halophenones with alkyl amides, which are not discussed in this publication due to their problematic reactivity in the Camps cyclization.

28. K<sub>3</sub>PO<sub>4</sub> was employed for reactions with 2-iodophenones due to the superiority of K<sub>3</sub>PO<sub>4</sub> for the facilitation of Cu-catalyzed amidation with aryl iodides reported in our earlier work (Reference 24b).


29. (a) Klapars, A.; Buchwald, S. L. *J. Am. Chem. Soc.* **2002**, *124*, 14844-14845. (b) Antilla, J. C.; Baskin, J. M.; Barder, T. E.; Buchwald, S. L. *J. Org. Chem.* **2004**, *69*, 5578-5587.
30. For example, *N*-(2-acetyl-phenyl)-*n*-hexanamide (**32**) cyclized to afford 25% of 4-methyl-3-*n*-butyl-2-quinolone (**33**) and 49% of 2-*n*-pentyl-4-quinolone (**34**).
31. (a) Gribble, G. W.; Bousquet, F. P. *Tetrahedron* **1971**, *27*, 3785-3794. (b) Mudry, C. A.; Frasca, A. R. *Tetrahedron* **1973**, *29*, 603-613.
32. Grammaticakis, P. *Bull. Soc. Chim. Fr.* **1953**, 93-99.
33. Shirakawa, N.; Tomioka, H.; Koizumi, M.; Takeuchi, M.; Sugiyama, H.; Okada, M.; Yoshimoto, M.; Iwane, Y.; Murakami, Y. Isonicotinanilide Derivatives, Process for Preparing the Same and Plant Growth Regulator Containing the Same. Eur. Pat. Appl. 48998, 1982.
34. Soloshonok, V. A.; Cai, C.; Hruby, V. J.; Meervelt, L. V.; Yamazaki, T. *J. Org. Chem.* **2000**, *65*, 6688-6696.
35. Amino phénones, leur preparation et leur utilization en thérapeutique. Fr. Patent 2121391, 1972.
36. Kövendi, A.; Kircz, M. *Chem. Ber.* **1965**, *98*, 1049-1059.
37. Möhrle, H.; Gerloff, J. *Arch. Pharm.* **1979**, *312*, 219-230.
38. (a) Troger, J.; Dunker, E. *J. Prakt. Chem.* **1925**, *109*, 88-123. (b) Jayabalan, L.; Shanmugam, P. *Synthesis* **1991**, 217-220.
39. (a) Gottstein, W. J.; Roberts, H.; Wells, I. C.; Cheney, L. C. *J. Org. Chem.* **1964**, *29*, 3065-3067. (b) Cheney, L. C.; Gottstein, W. J. Cinchoninic Acids and Use in Process for Quinolinols. US Patent 3301859, 1967.
40. Shanmugam, P.; Lakshminarayana, P. *Tet. Lett.* **1971**, *25*, 2323-2324.
41. Searles, A. L.; Lindwall, H. G. *J. Am. Chem. Soc.* **1946**, *68*, 988-990.
42. Back, T. G.; Parvez, M.; Wulff, J. E. *J. Org. Chem.* **2003**, *68*, 2223-2233.
43. (a) Lee, J.; Ha, J. D.; Cha, J. K. *J. Am. Chem. Soc.* **1997**, *119*, 8127-8128. (b) Ishikura, M.; Ida, W.; Yanada, K. *Tetrahedron* **2006**, *62*, 1015-1024.
44. Fleming, I.; Woolias, M. *J. Chem. Soc., Perkin Trans. 1* **1979**, *3*, 829-837.
45. Procedure for the synthesis of 2-bromo-5-methoxypropiophenone was modified from the procedure for the synthesis of *o*-bromopropiophenone in Wang, S.; Morrow, G. W.; Swenton, J. S. *J. Org. Chem.* **1989**, *54*, 5364-5371.



## **V. Appendix A: Selected NMR Spectra**



(16)




Current Data Parameters  
 NAME CJ-2-20  
 EXPNO 1  
 PROCNO 1

F2 - Acquisition Parameters  
 Date\_ 20061201  
 Time 11.05  
 INSTRUM spect  
 PROBHD 5 mm BBO BB-1H  
 PULPROG zg30  
 TD 65536  
 SOLVENT CDCl3  
 NS 16  
 DS 2  
 SWH 8278.146 Hz  
 FIDRES 0.126314 Hz  
 AQ 3.9584243 sec  
 RG 228.1  
 DW 60.400 usec  
 DE 6.00 usec  
 TE 293.2 K  
 D1 1.0000000 sec  
 TDD 1

\*\*\*\*\* CHANNEL f1 \*\*\*\*\*  
 NUCL1 1H  
 P1 15.07 usec  
 PL1 0.00 dB  
 SFO1 400.1324710 MHz

F2 - Processing parameters  
 S1 65536  
 SF 400.1311021 MHz  
 WDW no  
 SSB 0  
 LB 0.00 Hz  
 GB 0  
 PC 1.00




Current Data Parameters  
 NAME CJ-2-20Cl3meod  
 EXPNO 1  
 PROCNO 1

F2 - Acquisition Parameters  
 Date\_ 20070316  
 Time 12.28  
 INSTRUM spect  
 PROBHD 5 mm BBO BB-1H  
 PULPROG zgpg30  
 TD 65536  
 SOLVENT MeOD  
 NS 1597  
 DS 2  
 SWH 23980.814 Hz  
 FIDRES 0.365918 Hz  
 AQ 1.3664756 sec  
 RG 8152  
 DW 20.850 usec  
 DE 6.00 usec  
 TE 294.2 K  
 D1 2.0000000 sec  
 d13 0.0300000 sec  
 DELTA 1.8999998 sec  
 TDD 1

\*\*\*\*\* CHANNEL f1 \*\*\*\*\*  
 NUCL1 13C  
 P1 9.75 usec  
 PL1 -3.00 dB  
 SFO1 100.6228298 MHz

\*\*\*\*\* CHANNEL f2 \*\*\*\*\*  
 CPDPRG2 waltz16  
 NUCL2 1H  
 PCPD2 90.00 usec  
 PL2 -1.00 dB  
 PL12 14.52 dB  
 PL13 18.00 dB  
 SFO2 400.1316003 MHz

F2 - Processing parameters  
 S1 65536  
 SF 100.6126744 MHz  
 WDW no  
 SSB 0  
 LB 0.00 Hz  
 GB 0  
 PC 1.40




Current Data Parameters  
NAME CU-2-19  
EXPNO 1  
PROCNO 1


F2 - Acquisition Parameters  
Date\_ 20061130  
Time 10.30  
INSTRUM spect  
PROBHD 5 mm QNP 1H/13  
PULPROG zg30  
TD 65536  
SOLVHNT MeOD  
NS 14  
DS 2  
SWH 8278.146 Hz  
FIDRES 0.126314 Hz  
AQ 3.9584243 sec  
RG 645.1  
DW 40.400 usec  
DE 5.00 usec  
TE 293.2 K  
D1 1.0000000 sec  
TD0 1

===== CHANNEL f1 =====  
NUC1 13C  
P1 14.00 usec  
PL1 0.00 dB  
SFO1 400.1324710 MHz

F2 - Processing parameters  
SI 65536  
SF 400.130083 MHz  
WDW no  
SSB 0  
LB 0.00 Hz  
GB 0  
PC 1.00

STANDARD CARBON PARAMETERS  
Pulse Sequence: sput  
Solvent: CD3OD  
Ambient temperature  
User: 1-14-07  
File: C1-2-19cis  
SNOVA-301 "zippy"  
PULSE SEQUENCE  
3s1s2 - delay 9.763 sec  
Pulse 93.4 degrees  
Acq. time 1.730 sec  
FREQ 37735.8 Hz  
136Z repetitions  
OBSERVE C13 - 323.265824 MHz  
DECUPLE H1 - 500.132471 MHz  
Power 37 dB  
Cont. transmit on  
VOLT2-18 regulated  
DATA PROCESSING  
Line broadening 0.2 Hz  
SI size 131672  
Total time 2 hr, 29 min, 2 sec





(18)




Current Data Parameters  
 NAME CJ-1-297  
 EXPRNO 1  
 PROCNO 1

F2 - Acquisition Parameters  
 Date\_ 20061115  
 Time 11.17  
 INSTRUM spect  
 PROBRD 5 mm QNP 1H/13  
 PULPROG zg30  
 TD 65536  
 SOLVENT MeOD  
 NS 16  
 DS 2  
 SWH 8278.146 Hz  
 FIDRES 0.126314 Hz  
 AQ 3.9584243 sec  
 RG 342  
 CW 60.400 usec  
 DE 6.00 usec  
 TE 292.2 K  
 D1 1.0000000 sec  
 TDO 1


\*\*\*\*\* CHANNEL f1 \*\*\*\*\*  
 NUC1 13  
 P1 14.00 usec  
 PL1 0.00 dB  
 SFO1 400.1324710 MHz


F2 - Processing parameters  
 SI 32768  
 SF 400.1300088 MHz  
 MDW NO  
 SGB 0  
 LB 0.00 Hz  
 GB 0  
 PC 1.00



STANDARD CARBON PARAMETERS

Pulse Sequence: zgpg30  
 Solvent: CD3OD  
 Ambient temperature  
 User: j-24-57  
 File: CJ-1-297c33  
 INOVA-500 (4ppp).  
 PULSE SEQUENCE  
 Relax. delay 0.700 sec  
 Pulse prg. 30 degrees  
 AQC: time 1.700 sec  
 Width 37730.0 Hz  
 1280 repetitions  
 OBSERVE CH: 13  
 DECOUPLE CH: 500.2352400 MHz  
 Power 37 dB  
 continuously on  
 WALTZ-16 modulated  
 DATA PROCESSING  
 Line broadening 0.3 Hz  
 FT size 131072  
 Total time 5 hr, 23 min, 2 sec





Current Data Parameters  
 NAME CJ-1-294  
 EXPNO 1  
 PROCNO 1

F2 - Acquisition Parameters  
 Date\_ 20051116  
 Time 13.13  
 INSTRUM spect  
 PROBRD 5 mm QNP 1H/13  
 PULPROG zg30  
 TD 65536  
 SOLVENT MeOD  
 NS 16  
 DS 2  
 SWH 8278.146 Hz  
 FIDRES 0.126314 Hz  
 AQ 3.9584243 sec  
 RG 322.5  
 DW 60.400 usec  
 DE 8.00 usec  
 TE 292.2 K  
 D1 1.0000000 sec  
 TDD 1


===== CHANNEL f1 =====  
 NUC1 13  
 P1 14.00 usec  
 PL 0.00 dB  
 SFO1 400.1324710 MHz


F2 - Processing parameters  
 SI 65536  
 SF 400.1300087 MHz  
 WDM no  
 SSB no  
 LB 0.00 Hz  
 GB 0  
 CB 0  
 PC 1.00

CJ-1-294c13  
 Pulse Sequence: zgpg1  
 Solvent: CD3OD  
 Ambient Temperature  
 User: 1-14-07  
 File: CJ-1-294c13  
 INOVA-500 "c13py"


===== CHANNEL f1 =====  
 NUC1 13  
 P1 14.00 usec  
 PL 0.00 dB  
 SFO1 400.1324710 MHz

F2 - Processing parameters  
 SI 65536  
 SF 400.1300087 MHz  
 WDM no  
 SSB no  
 LB 0.00 Hz  
 GB 0  
 CB 0  
 PC 1.00





(21) CD<sub>3</sub>OD




Current Data Parameters  
 NAME CJ-2-11-2  
 EXPNO 1  
 PROCNO 1


F2 - Acquisition Parameters  
 Date\_ 20081207  
 Time 14.31  
 INSTRUM spect  
 PROBR2 5 mm QNP 1H/13  
 PULPROG zg30  
 TD 65536  
 SOLVENT MeOD  
 NS 16  
 DS 2  
 SWH 6276.146 Hz  
 FIDRES 0.126314 Hz  
 AQ 3.958423 sec  
 RG 456.1  
 DM 60.400 usec  
 DE 6.00 usec  
 TE 293.2 K  
 DI 1.0000000 sec  
 TDO 1

----- CHANNEL f1 -----  
 NUCL1 13C  
 P1 14.00 usec  
 PL1 0.00 dB  
 SFO1 400.1264710 MHz

F2 - Processing parameters  
 SI 65536  
 SF 400.1300093 MHz  
 WDW HC  
 SSB 0  
 LB 0.00 Hz  
 GB 0  
 PC 1.00

STANDARD CARBON PARAMETERS  
 Pulse Sequence: s2pu1  
 Solvent: CD3OD  
 Ambient Temperature  
 User: 1-11-07  
 File: CJ-2-13C132  
 INOVA-500 "sippy"  
 PULSE SEQUENCE  
 Relax. delay 8.763 sec  
 Pulse 83.8 degree  
 Acq. time 1.736 sec  
 Width 37735.8 Hz  
 2527 repetitions  
 OBSERVE C13, 125.7434591 MHz  
 DECUPLE H1, 500.2352463 MHz  
 Power 37 db  
 continuously on  
 WALTZ-16 modulated  
 SITA PULSING  
 Line Broadening 0.3 Hz  
 FT size 131872  
 Total time 3 hr, 29 min, 2 sec





(22)




Current Data Parameters  
 NAME CJ-1-293  
 EXPNO 1  
 PROCNO 1

F2 - Acquisition Parameters  
 Date\_ 20061115  
 Time 11:04  
 INSTRUM spect  
 PROBHD 5 mm QNP 1H/13  
 PULPROG zg30  
 TD 65536  
 SOLVENT MeOD  
 NS 2  
 DS 16  
 SWH 8278.146 Hz  
 FIDRES 0.126314 Hz  
 AQ 1.9584243 sec  
 RG 57  
 DM 60.400 usec  
 DE 6.00 usec  
 TE 292.2 K  
 D1 1.0000000 sec  
 TDO 1


===== CHANNEL f1 =====  
 NUC1 1H  
 P1 14.00 usec  
 PL1 0.00 dB  
 SFO1 400.1324710 MHz

F2 - Processing parameters  
 SI 65536  
 SF 400.1300893 MHz  
 WDM no  
 SSB 0  
 LB 0.00 Hz  
 GB 0  
 PC 1.00



1.01  
1.00  
2.14  
3.05  
1.00

CJ-1-293  
 Pulse Sequence: zgpg30  
 Solvent: CD3OD  
 Ambient temperature  
 User: 1-4-07  
 File: CJ-2-293c13  
 INOVA-300 "zgpg30"  
 PULSE SEQUENCE  
 Relax. delay 2.700 sec  
 Pulse 65.4 usec  
 Acq. time 1.700 sec  
 Width 2720.0 Hz  
 1200 repetitions  
 OBSERVE C13, 125.7623994 MHz  
 DECOUPLE H1, 500.2352483 MHz  
 Power 37 dB  
 Continuously on  
 WALTZ-16 modulated  
 DATA PROCESSING  
 Line broadening 0.3 Hz  
 FT size 32768  
 Total time 3 hr, 29 min, 2 sec





CDCl<sub>3</sub>

CD<sub>3</sub>OD



(23)



Current Data Parameters  
NAME: CJ-1-296  
EXPNO: 1  
PROCNO: 1


F2 - Acquisition Parameters  
Date\_: 20061115  
Time: 11.11  
INSTRUM: spect  
PROBHD: 5 mm QNP 1H/13  
PULPROG: zg30  
TD: 65536  
SOLVENT: MeOD  
NS: 16  
DS: 2  
SWH: 8276.146 Hz  
FIDRES: 0.126314 Hz  
AQ: 3.9584243 sec  
RG: 322.5  
DM: 60.400 usec  
DE: 6.00 usec  
TE: 292.2 K  
D1: 1.0000000 sec  
YD0: 1

===== CHANNEL f1 =====  
NUC1: 1H  
P1: 14.00 usec  
PL1: 0.00 dB  
SFO1: 400.1324710 MHz

F2 - Processing parameters  
SI: 65536  
SF: 400.1300000 MHz  
WDW: no  
SSB: 0  
LB: 0.00 Hz  
GB: 0  
PC: 1.00

CJ-1-296c13  
Pulse Sequence: zgpg30  
Solvent: CD3OD  
Ambient Temperature  
Date\_: 1-16-07  
File: CJ-1-296c13  
IMD04-500 "zgpg30"



PULSE SEQUENCE  
Relax. delay 8.765 sec  
Pulse pr. 4 degrees  
Acq. time 1.734 sec  
Width 37735.8 Hz  
2700 repetitions  
CLOCKWIS C19, 130.7826251 MHz  
SECCUPLE M1, 524.2824483 MHz  
Power 37 dB  
continuously on  
WALTZ-16 modulated  
DATA PROCESSING  
Line broadening 0.3 Hz  
ST size 131072  
Total time 3 hr, 26 min, 1 sec







(24)




Current Data Parameters  
NAME CJ-2-14  
EXPNO 1  
PROCNO 1


F2 - Acquisition Parameters  
Date\_ 20061122  
Time 15.10  
INSTRUM spect  
PROBHD 5 mm QNP 1H/13  
PULPROG sg30  
TD 65536  
SOLVENT CDCl3  
NS 2  
DS 2  
SWH 8278.146 Hz  
FIDRES 0.126314 Hz  
AQ 3.9584243 sec  
RG 574.7  
DM 60.400 usec  
DE 6.00 usec  
TE 293.2 K  
D1 1.0000000 sec  
TD0 1

===== CHANNEL f1 =====  
NUC1 1H  
P1 14.00 usec  
PL1 0.00 dB  
SFO1 400.1324710 MHz


F2 - Processing parameters  
SI 65536  
SF 400.1315833 MHz  
WDW Ho  
SSB 0  
LB 0.00 Hz  
GB 0  
PC 1.00

CJ-2-14e13  
Pulse Sequence: g2pul  
Solvent: CD3OD  
Ambient Temperature  
User: i-14-17  
File: CJ-2-14e13  
Innova-300 "xippy"  
PULSE SEQUENCE  
Relax. delay 2.753 sec  
Pulse 65.4 degrees  
Acq. time 1.736 sec  
Width 3776.8 Hz  
2048 repetitions  
OBSERVE Ch1, 125.760000 MHz  
MAGNET Ch1, 300.1352453 MHz  
Power 37 dB  
Continuously on  
VOLTAGE modulated  
DATA PROCESSING  
Line broadening 0.3 Hz  
FT size 131072  
Total time 2 hr, 25 min, 3 sec





(25)



Current Data Parameters  
 NAME CJ-1-293-3  
 EXPNO 1  
 PROCNO 1


F2 - Acquisition Parameters  
 Date\_ 20070321  
 Time 13:58  
 INSTRUM spect  
 PROBP2 5 mm QNP 1H/13  
 PULPROG zg30  
 TD 65536  
 SOLVENT MeOD  
 NS 2  
 DS 2  
 SWH 8278.146 Hz  
 FIDRES 0.126314 Hz  
 AQ 3.9584243 sec  
 RG 362  
 DM 60.400 usec  
 DE 6.00 usec  
 TE 293.2 K  
 D1 1.0000000 sec  
 TDC 1



===== CHANNEL f1 =====  
 NUC1 13C  
 P1 14.00 usec  
 PL1 0.98 dB  
 SFO1 400.1324710 MHz

F2 - Processing parameters  
 SI 65536  
 SF 400.1300899 MHz  
 MM 0  
 SSB 0  
 LB 0.00 Hz  
 GB 0  
 PC 1.00

STANDARD CARBON PARAMETERS

Pulse Sequence: sput  
 Solvent: CD3OD  
 Ambient Temperature  
 NSPP: 1-13-2  
 File: CJ-1-293-3  
 INOVA-300 "tippy"  
 PULSE SEQUENCE  
 Relax. delay 8.750 sec  
 Pulse prg. sput  
 Acq. time 1.750 sec  
 Width 3720.0 Hz  
 SFO1 400.1324710 MHz  
 OBSERVE C13, 125.7680000 MHz  
 SCORPUL 76.88000000 MHz  
 Power 37 dB  
 CONT Inversely on  
 WALTZ-16 modulated  
 DATA PROCESSING  
 Line broadening 0.3 Hz  
 FT size 131072  
 Total time 3 hr, 20 min, 2 sec






Current Data Parameters  
 NAME CJ-2-132  
 EXPNO 1  
 PROCNO 1

F2 - Acquisition Parameters  
 Date\_ 20070417  
 Time 16.34  
 INSTRUM spect  
 PROBRD 5 mm BBO BB-1H  
 PULPROG zg30  
 TD 65536  
 SOLVENT MeOD  
 NS 16  
 DS 2  
 SSB 8278.146 Hz  
 FIDRES 0.126124 Hz  
 AQ 3.998422 sec  
 RG 228.1  
 DM 60.400 usec  
 DE 6.00 usec  
 TE 683.2 K  
 D1 1.0000000 sec  
 TDO 1

\*\*\*\*\* CHANNEL f1 \*\*\*\*\*  
 NUCL 1H  
 P1 15.07 usec  
 PL1 0.00 dB  
 SFO1 400.1324710 MHz

F2 - Processing parameters  
 SI 65536  
 SF 400.1308075 MHz  
 MDW no  
 SSR 0  
 LB 0.00 Hz  
 GB 0  
 PC 1.00




Current Data Parameters  
 NAME CJ-2-132c13  
 EXPNO 1  
 PROCNO 1

F2 - Acquisition Parameters  
 Date\_ 20070429  
 Time 16.56  
 INSTRUM spect  
 PROBRD 5 mm BBO BB-1H  
 PULPROG zgpg30  
 TD 65536  
 SOLVENT MeOD  
 NS 945  
 DS 2  
 SSB 23980.814 Hz  
 FIDRES 0.365918 Hz  
 AQ 1.3664756 sec  
 RG 8192  
 DM 20.850 usec  
 DE 6.00 usec  
 TE 294.2 K  
 D1 2.00008000 sec  
 S11 0.03000000 sec  
 DELTA 1.89999998 sec  
 TDO 1

\*\*\*\*\* CHANNEL f1 \*\*\*\*\*  
 NUCL 13C  
 P1 8.75 usec  
 PL1 -1.00 dB  
 SFO1 100.6226288 MHz

\*\*\*\*\* CHANNEL f2 \*\*\*\*\*  
 CDPRG2 waltz16  
 NUCL2 1H  
 PCPRG2 90.00 usec  
 PL2 -1.00 dB  
 PL12 14.52 dB  
 PL13 18.00 dB  
 SFO2 400.1316003 MHz

F2 - Processing parameters  
 SI 65536  
 SF 100.6126918 MHz  
 MDW no  
 SSR 0  
 LB 0.00 Hz  
 GB 0  
 PC 1.40




Current Data Parameters  
 NAME CJ-2-104-2  
 EXPNO 1  
 PROCNO 1

F2 - Acquisition Parameters  
 Date\_ 20070307  
 Time 9.33  
 INSTRUM spect  
 PROBHD 5 mm BBO BB-1H  
 PULPROG zg30  
 TD 65536  
 SOLVENT MeOD  
 NS 16  
 DS 2  
 SWH 8278.146 Hz  
 FIDRES 0.126314 Hz  
 AQ 3.9584243 sec  
 RG 128  
 DW 60.400 usec  
 DE 5.00 usec  
 TE 294.2 K  
 DL 1.0000000 sec  
 TDO 1

\*\*\*\*\* CHANNEL f1 \*\*\*\*\*  
 NUCL1 1H  
 P1 15.07 usec  
 PLL 0.00 dB  
 SFO1 400.1324710 MHz

F2 - Processing parameters  
 SI 65536  
 SF 400.1300983 MHz  
 MW no  
 SSB 0  
 LB 0.00 Hz  
 GB 0  
 PC 1.00




Current Data Parameters  
 NAME CJ-2-104c13-2  
 EXPNO 1  
 PROCNO 1


F2 - Acquisition Parameters  
 Date\_ 20070309  
 Time 15.23  
 INSTRUM spect  
 PROBHD 5 mm BBO BB-1H  
 PULPROG zgpg30  
 TD 65536  
 SOLVENT MeOD  
 NS 128  
 DS 2  
 SWH 23980.814 Hz  
 FIDRES 0.365918 Hz  
 AQ 1.3664756 sec  
 RG 18390.6  
 DW 20.850 usec  
 DE 6.00 usec  
 TE 294.2 K  
 DL 2.0000000 sec  
 d11 0.03800000 sec  
 DELTA 1.89999998 sec  
 TDO 1

\*\*\*\*\* CHANNEL f1 \*\*\*\*\*  
 NUCL1 13C  
 P1 8.75 usec  
 PL1 -3.00 dB  
 SFO1 100.6228298 MHz

\*\*\*\*\* CHANNEL f2 \*\*\*\*\*  
 CPDPRG2 waltz16  
 NUCL2 1H  
 PCPD2 90.00 usec  
 PL2 -1.00 dB  
 PL12 14.52 dB  
 PL13 18.00 dB  
 SFO2 400.1316005 MHz

F2 - Processing parameters  
 SI 65536  
 SF 100.6127048 MHz  
 MW no  
 SSB 0  
 LB 0.00 Hz  
 GB 0  
 PC 1.40






Current Data Parameters  
 NAME CV-2-114-2  
 EXPNO 1  
 PROCNO 1

F2 - Acquisition Parameters  
 Date\_ 20070129  
 Time 13.43  
 INSTRUM spect  
 PROBHD 5 mm BBO BB-1H  
 PULPROG zg30  
 TD 65536  
 SOLVENT MeOD  
 NS 16  
 DS 2  
 SWH 8278.146 Hz  
 FIDRES 0.126314 Hz  
 AQ 3.9584243 sec  
 RG 128  
 DW 60.400 usec  
 DE 8.00 usec  
 TE 293.2 K  
 D1 1.0000000 sec  
 TDO 1


\*\*\*\*\* CHANNEL F1 \*\*\*\*\*  
 NUCL1 1H  
 P1 15.07 usec  
 PL1 0.00 dB  
 SF01 400.1324710 MHz


F2 - Processing parameters  
 SI 65536  
 SF 400.1300082 MHz  
 WDW wc  
 SSB 0  
 LB 0.00 Hz  
 GB 0  
 PC 1.00



STANDARD CARBON PARAMETERS

Pulse Sequence: s2pul  
 Solvent: CD3OD  
 Ambient temperature  
 User: i-11-5P  
 File: CV-2-114-2  
 EXPNO-16 "1699"  
 PULSE SEQUENCE  
 Relax. delay 0.763 sec  
 Pulse pr. 0.000000 sec  
 Acc. time 1.736 sec  
 Ufch 37796.0 Hz  
 15 positions  
 OBSERVE CH 125.626555 MHz  
 DECOUPLE CH 509.2321683 MHz  
 Power 37 dB  
 Continuously on  
 GALTZ-18 modulated  
 DATA PROCESSING  
 Line broadening 0.3 Hz  
 FT size 131072  
 Total time 3 hr, 26 min, 2 sec






```

Current Data Parameters
NAME      CR-2-23fhex
EXPNO     1
PROCNO    1

F2 - Acquisition Parameters
Date_     20070511
Time      10.53
INSTRUM   spect
PROBHD    5 mm QNP 1H/13
PULPROG   zg30
TD         65536
SOLVENT   CDCl3
NS         16
DS         2
SMB       8279.146 Hz
FIDRES    0.126314 Hz
AQ         3.9584243 sec
RG         256
DM         60.400 usec
DE         6.00 usec
TE         293.2 K
D1         1.0000000 sec
TD0        1

===== CHANNEL f1 =====
NUC1       13C
P1         14.00 usec
PL1        0.00 dB
SFO1       400.1324710 MHz

F2 - Processing parameters
SI         65536
SF         400.1300068 MHz
WDW        no
SSB        0
LB         0.00 Hz
GB         0
PC         1.00
  
```



```


Current Data Parameters
NAME      CR-2-23fhexc13
EXPNO     1
PROCNO    1


F2 - Acquisition Parameters
Date_     20070512
Time      12.15
INSTRUM   spect
PROBHD    5 mm BBO BB-1H
PULPROG   zgpg30
TD         65536
SOLVENT   cdcl3
NS         3108
DS         2
SMB       23980.814 Hz
FIDRES    0.365910 Hz
AQ         1.3664756 sec
RG         8192
DM         20.850 usec
DE         6.00 usec
TE         293.2 K
D1         2.0000000 sec
d11        0.93000000 sec
DELTA     1.8989998 sec
TD0        1

===== CHANNEL f1 =====
NUC1       13C
P1         8.75 usec
PL1        -1.00 dB
SFO1       100.6228298 MHz

===== CHANNEL f2 =====
CPDPRG2   waltz16
NUC2       1H
PCPD2     90.00 usec
PL2        -1.80 dB
PL12      14.52 dB
PL13      14.00 dB
SFO2       400.1316005 MHz

F2 - Processing parameters
SI         65536
SF         100.6127921 MHz
WDW        no
SSB        0
LB         0.00 Hz
GB         0
PC         1.40
  
```






Current Data Parameters  
 NAME CJ-2-239ben  
 EXPNO 1  
 PROCNO 1

F2 - Acquisition Parameters  
 Date\_ 20070511  
 Time 8.34  
 INSTRUM spect  
 PPOBWD 5 mm BBO BB-1H  
 PULPROG zg30  
 TD 65536  
 SOLVENT CDCl3  
 NS 16  
 DS 2  
 SWH 8278.146 Hz  
 FIDRES 0.126314 Hz  
 AQ 3.9584243 sec  
 RG 71.8  
 INW 40.400 usec  
 DE 6.00 usec  
 TE 293.2 K  
 DI 1.0000000 sec  
 TDO 1

\*\*\*\*\* CHANNEL f1 \*\*\*\*\*  
 NUCL 1H  
 P1 13.07 usec  
 PL1 0.00 dB  
 SFO1 400.1324710 MHz

F2 - Processing parameters  
 SI 65536  
 SF 400.1300053 MHz  
 MDW no  
 SSB 0  
 LB 0.00 Hz  
 GB 0  
 PC 1.00




Current Data Parameters  
 NAME CJ-2-239bencl3  
 EXPNO 1  
 PROCNO 1

F2 - Acquisition Parameters  
 Date\_ 20070511  
 Time 9.06  
 INSTRUM spect  
 PPOBWD 5 mm BBO BB-1H  
 PULPROG zgpg30  
 TD 65536  
 SOLVENT CDCl3  
 NS 128  
 DS 2  
 SWH 23980.814 Hz  
 FIDRES 0.365918 Hz  
 AQ 1.3664736 sec  
 RG 14586.3  
 INW 28.850 usec  
 DE 6.00 usec  
 TE 294.2 K  
 DI 2.0000000 sec  
 d11 0.0300000 sec  
 DELTA 1.8999999 sec  
 TDO 1

\*\*\*\*\* CHANNEL f1 \*\*\*\*\*  
 NUCL 13C  
 P1 8.75 usec  
 PL1 -3.00 dB  
 SFO1 100.6228298 MHz

\*\*\*\*\* CHANNEL f2 \*\*\*\*\*  
 CPDPRG2 waltz16  
 NUCL2 1H  
 P12 90.00 usec  
 PL2 -1.00 dB  
 PL12 14.52 dB  
 PL13 18.00 dB  
 SFO2 400.1316003 MHz

F2 - Processing parameters  
 SI 65536  
 SF 100.6127545 MHz  
 MDW no  
 SSB 0  
 LB 0.00 Hz  
 GB 0  
 PC 1.40







Current Data Parameters  
NAME CJ-1-289-2  
EXPRO 1  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20070406  
Time 9.55  
INSTRUM spect  
PROBHD 5 mm BBO BB-1H  
PULPROG zg30  
TD 65536  
SOLVENT CDC13  
NS 16  
DS 2  
SWH 8278.146 Hz  
FIDRES 0.128114 Hz  
AQ 3.9584243 sec  
RG 256  
DM 60.400 usec  
DE 6.40 usec  
TE 293.2 K  
D1 1.0000000 sec  
TDO 1

===== CHANNEL f1 =====  
NUC1 1H  
P1 15.87 usec  
PL1 0.80 dB  
SFO1 400.1324710 MHz

F2 - Processing Parameters  
SI 65536  
SF 400.1300064 MHz  
WDW no  
SSB C  
LB 0.00 Hz  
GB 0  
PC 1.00




Current Data Parameters  
NAME CJ-1-289-2c132  
EXPRO 1  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20070406  
Time 10.36  
INSTRUM spect  
PROBHD 5 mm QNP 1H/13  
PULPROG zgpg30  
TD 65536  
SOLVENT CDC13  
NS 128  
DS 2  
SWH 33980.816 Hz  
FIDRES 0.365918 Hz  
AQ 1.3664756 sec  
RG 4096  
DM 28.856 usec  
DE 6.08 usec  
TE 293.2 K  
D1 2.0000008 sec  
d11 0.0300000 sec  
DELTA 1.8999998 sec  
TDO 1



===== CHANNEL f1 =====  
NUC1 13C  
P1 9.38 usec  
PL1 0.80 dB  
SFO1 100.6228298 MHz

===== CHANNEL f2 =====  
CPDPRG2 waltz16  
NUC2 1H  
PCPD2 90.80 usec  
PL2 0.80 dB  
PL12 16.10 dB  
PL13 19.00 dB  
SFO2 400.1316095 MHz

F2 - Processing Parameters  
SI 65536  
SF 100.6127528 MHz  
WDW no  
SSB 0  
LB 0.00 Hz  
GB 0  
PC 1.40








Current Data Parameters  
 NAME CJ-2-119  
 EXPNO 1  
 PROCNO 1

F2 - Acquisition Parameters  
 Date\_ 20070322  
 Time 12.22  
 INSTRUM spect  
 PROBRD 5 mm BBO BB-1H  
 PULPROG zg30  
 TD 65536  
 SOLVENT CDCl3  
 NS 16  
 DS 2  
 SFO1 3278.146 Hz  
 FIDRES 0.126314 Hz  
 AQ 1.9584243 sec  
 RG 128  
 DW 60.400 usec  
 DE 8.00 usec  
 TE 293.2 K  
 D1 1.0000000 sec  
 TDD 1

===== CHANNEL F1 =====  
 NUC1 1H  
 P1 15.47 usec  
 PL1 0.00 dB  
 SFO1 400.1324710 MHz

F2 - Processing parameters  
 SI 65536  
 SF 400.1300642 MHz  
 MDW no  
 SSB 0  
 LB 0.00 Hz  
 GB 0  
 PC 1.00




Current Data Parameters  
 NAME CJ-2-119e13  
 EXPNO 1  
 PROCNO 1

F2 - Acquisition Parameters  
 Date\_ 20070322  
 Time 12.34  
 INSTRUM spect  
 PROBRD 5 mm BBO BB-1H  
 PULPROG zgpg30  
 TD 65536  
 SOLVENT CDCl3  
 NS 128  
 DS 2  
 SFO1 23990.814 Hz  
 FIDRES 0.368518 Hz  
 AQ 1.3664756 sec  
 RG 18390.4  
 DW 26.850 usec  
 DE 8.00 usec  
 TE 293.2 K  
 D1 2.0000000 sec  
 d11 0.0300000 sec  
 DELTA 1.8999999 sec  
 TDD 1

===== CHANNEL F1 =====  
 NUC1 13C  
 P1 8.75 usec  
 PL1 -3.00 dB  
 SFO1 100.6228298 MHz

===== CHANNEL F2 =====  
 CPDPRG2 waltz16  
 NUC2 1H  
 PCPD2 90.00 usec  
 PL2 -1.00 dB  
 PL12 14.52 dB  
 PL13 18.00 dB  
 SFO2 400.1316005 MHz

F2 - Processing parameters  
 SI 65536  
 SF 100.6127587 MHz  
 MDW no  
 SSB 0  
 LB 0.00 Hz  
 GB 0  
 PC 1.40




Current Data Parameters  
 NAME CJ-2-39-2  
 EXPNO 1  
 PROCNO 1

F2 - Acquisition Parameters  
 Date\_ 20070511  
 Time 9.13  
 INSTRUM spect  
 PROBRD 5 mm BBO BB-1H  
 PULPROG zg30  
 TD 65536  
 SOLVENT cdc13  
 NS 16  
 DS 2  
 SWH 8278.146 Hz  
 FIDRES 0.126314 Hz  
 AQ 3.9584243 sec  
 RG 28.5  
 DW 60.400 usec  
 DE 6.00 usec  
 TE 293.2 K  
 D1 1.0000000 sec  
 TDO 1

\*\*\*\*\* CHANNEL f1 \*\*\*\*\*  
 NUC1 1H  
 P1 15.97 usec  
 PL1 0.00 dB  
 SFO1 400.1324710 MHz

F2 - Processing parameters  
 SI 65536  
 SF 400.1300056 MHz  
 MDW no  
 SSB 0  
 LB 0.00 Hz  
 GB 0  
 PC 1.00




Current Data Parameters  
 NAME CJ-2-19c13  
 EXPNO 1  
 PROCNO 1

F2 - Acquisition Parameters  
 Date\_ 20070511  
 Time 9.25  
 INSTRUM spect  
 PROBRD 5 mm BBO BB-1H  
 PULPROG zgpg30  
 TD 65536  
 SOLVENT cdc13  
 NS 128  
 DS 2  
 SWH 23988.814 Hz  
 FIDRES 0.365918 Hz  
 AQ 1.3684756 sec  
 RG 13004  
 DW 20.850 usec  
 DE 6.00 usec  
 TE 294.2 K  
 D1 2.0000000 sec  
 d11 0.0300000 sec  
 DELTA 1.8999999 sec  
 TDO 1

\*\*\*\*\* CHANNEL f1 \*\*\*\*\*  
 NUC1 13C  
 P1 8.75 usec  
 PL1 -3.00 dB  
 SFO1 100.6228298 MHz

\*\*\*\*\* CHANNEL f2 \*\*\*\*\*  
 CPDPRG2 waltz16  
 NUC2 1H  
 PCPDZ 90.00 usec  
 PL2 -1.00 dB  
 PL12 14.52 dB  
 PL13 18.00 dB  
 SFO2 400.1316005 MHz

F2 - Processing parameters  
 SI 65536  
 SF 100.6127718 MHz  
 MDW no  
 SSB 0  
 LB 0.60 Hz  
 GB 0  
 PC 1.40



## **VI. Appendix B: Curriculum Vitae**

472 Cambridge St. Apt. 3  
Cambridge, MA 02141

Phone: 908-304-4781  
E-mail: [carriepjones@gmail.com](mailto:carriepjones@gmail.com)

## Carrie Preston Jones

**Objective** An intellectually challenging position which utilizes my creativity, enthusiasm, and analytical and problem-solving skills

**Education** September 2005-present Massachusetts Institute of Technology, Cambridge, MA  
**Master of Science/Organic Chemistry** (Expected Sept. 2007)  
• Teaching Award 2006  
• MIT Presidential Fellow 2005-2006  
• Completed Master's thesis: *Development of a Copper-catalyzed Amidation-Base-promoted Cyclization Sequence for the Synthesis of 2-Aryl- and 2-Vinyl-4-quinolones*

September 1998-June 2002 Williams College, Williamstown, MA  
**Bachelor of Arts/Chemistry** June 2002  
• Highest Honors, Magna Cum Laude, Phi Beta Kappa, Sigma Xi  
• Chemistry GPA: 3.89; Career GPA: 3.78  
• Received ACS Connecticut Valley Section 2002 Achievement Award  
• Received 1999 CRC Press First-Year Chemist Achievement Award  
• Dean's List for all eight semesters  
• Completed year-long chemistry research thesis: *Metallomesogenic Platinum Complexes with 2,2'-Bipyridyl-Based Ligands: Progress Towards 1-D Conductive Materials*

**Work Experience** January 2006-present Buchwald Lab, MIT  
**Lab Research Assistant**  
• Developed a copper-catalyzed method for the synthesis of nitrogen heterocycles: 2-aryl-4-quinolones.  
• Research culminated in written thesis (above) and publication (below) and involved regular presentations at group meetings

September 2005-December 2005 MIT, Cambridge, MA  
**Teaching Assistant**  
• Held biweekly recitations and office hours for Course 5.13: Organic Chemistry (2<sup>nd</sup> semester), graded problem sets and exams

April 2003-July 2005 Merck & Co., Inc., Rahway, NJ  
**Chemist**  
• Worked in Medicinal Chemistry department performing organic synthesis of small molecules for drug discovery  
• Received promotion in Spring 2005  
• Presented work at Merck's annual Associate Research Symposium (June 2005)

September 2002-January 2003 Waynflete School, Portland, ME  
**Substitute Teacher**

June 2001-May 2002 Inorganic Chemistry Lab, Williams College  
**Lab Research Assistant**  
• Performed organic syntheses and scale-ups of bipyridyl-based ligands and inorganic syntheses of Pt-coordinated complexes  
• Research culminated in written thesis (above) and included two oral presentations

**Publications** “Sequential Cu-Catalyzed Amidation-Base-mediated Camps Cyclization: A Two-step Synthesis of 2-Aryl-4-quinolones from *ortho*-Halophenones.” Jones, C. P., Anderson, K. W., Buchwald, S. L. Manuscript submitted.

“A Highly Activated Catalyst System for the Heteroarylation of Acetone.” Liu, P., Lanza, T. J., Jewell, J. P., Jones, C. P., Hagmann, W. K., Lin, L. S. *Tetrahedron Lett.* 2003, **44**, 8869-8871.

“Mesomorphic Properties of Novel 2,2'-Bipyridines and Their Metal Complexes.” Park, L. Y., Fulmer, S. L., Hensley, L. A., Jones, C. P., McGehee, E. A., Scroggins, S. T., Walrod, M. D. Manuscript submitted.

**Skills**

Computer Proficiency: Microsoft Office, ChemDraw, Mac and PC systems; Chemistry Instrumentation: NMR, GC, GC-MS, LC-MS, HPLC, IR, silica chromatography, DSC, polarized optical microscopy, microwave